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1
Abstract
Joint modelling is the simultaneous modelling of longitudinal and survival data,
while taking into account a possible association between them. A common approach
in joint modelling studies is to assume that the repeated measurements follow a lin-
ear mixed effects model and the survival data is modelled using a Cox proportional
hazards model. The Cox model, however, requires a strong proportionality assump-
tion, which seems to be violated quite often. We, thus, propose the use of parametric
survival models. Additionally, joint modelling literature mainly deals with right-
censoring only and does not consider left-truncation, which can cause bias. The joint
model proposed here considers left-truncation and right-censoring.
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1 Literature Review
1.1 Introduction
This chapter describes the fundamentals of time-to-event and longitudinal analysis. For
time-to-event data the basic quantities, missing data mechanisms, the methods for time-
to-event data and diagnostics are described. For longitudinal analysis the missing data
mechanisms and the most common model used are mentioned. For joint analysis, different
approaches to parameter estimation and different modelling strategies are discussed. A gap
in the research of joint modelling to do with the use of parametric time-to-event models in
joint modelling is identified. This thesis will try to fill in that gap.
1.2 Time-To-Event Analysis
Survival Analysis (also known as time-to-event analysis) is the analysis of time from a start
point until the event of interest occurs (20). The survival time is the difference between
the two time-points i.e. the starting point and the endpoint (63).
1.2.1 Basic Quantities
Let T be a continuous random variable taking on values on [0,∞], which denotes time
interval until a predetermined event occurs. This event could be cancer appearance or
cancer metastasis, start time of smoking, death, etc.
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1.2.1.1 Cummulative Distribution Function The cummulative distribution func-
tion is the probability that the event will occur before time t, (85), (68):
F (t) = P (T ≤ t). (1)
This is an increasing function of t, taking values from 0 to 1.
1.2.1.2 Survival Function The survival function at time t is the probability that the
event will not occur before this time t (141), or the probability of surviving beyond time t
(9):
S(t) = P (T > t), (2)
where t ≥ 0. Survival function is a decreasing function equal to 1 at t = 0 and as the time
tends to infinity, it approaches zero (1).
The relation between the cummulative distribution function and the survival function is:
S(t) = 1− F (t). (3)
Thus, the survival function is the complement of the cummulative distribution function.
1.2.1.3 Probability Density Function The probability density function is the deriva-
tive of the cummulative distribution function(6):
f(t) =
dF (t)
dt
= −dS(t)
dt
. (4)
1.2.1.4 Hazard Function The hazard function is the instantaneous probability of an
event to occur within a small time interval t+ ∆t given that it has not occurred until time
2
t, (71), (68):
h(t) = lim
∆t→0
P [t ≤ T < t+ ∆t|T ≥ t]
∆t
. (5)
It is also called “conditional hazard rate” or “force of mortality” (73). The hazard function
can be obtained by dividing the density f(t) by the survival function S(t) (52):
h(t) =
f(t)
S(t)
. (6)
1.2.1.5 Cummulative Hazard Function The cummulative hazard function is the
integrated hazard function up to t (93) (68):
H(t) =
∫ t
0
h(u)du = − log [S(t)]. (7)
1.2.2 Missing Data Mechanisms
“Survival time” is the distance between the starting point and time when the event takes
place. There are cases, where there is a lack of observation of survival time. This lack of
observation is caused by two different mechanisms. The lack of observation may be due to
random factors (censoring) for each subject, or due to the selection process (truncation) in
the study (63). There are various cases of censoring and truncation, which are discussed
below.
Suppose that a subject takes part in a study. Suddenly, he decides to move to another
city. His last visit contains the latest information that is held about him. After he moved,
the information about what happened to him is missing. So, there is a lack of observation
on the right tail of the time-axis. This lack of observation is called right-censoring (63).
Let Ci and Ti denote the censoring and survival times respectively, observed for the i
th
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individual. Censoring indicator δi = I(Ti ≤ Ci), where I is the indicator of an event, thus
when right-censoring is present i.e. Ci < Ti, the censoring indicator δi = 0. When the
subject dies and is not right-censored Ti ≤ Ci, the censoring indicator δi = 1.
Consider a study where the subjects are interviewed about the age when they have first
used marijuana. One possible answer is that the respondents have used it, but they cannot
remember when this happened. So, the event of interest occurred at an age, prior to the
age that the interview is done. The exact age, however, is not known (71). This type of
lack of time observation is called left-censoring (63).
Another type of censoring, is the interval censoring. This happens when the subjects are
contacted at time intervals. Suppose that the individuals are contacted every two months.
The event of interest has not occurred by the second month. By the fourth month, however,
it has occurred. So, it is known that the event of interest has occurred at some time between
the second and fourth months, but the exact date is not known (63).
The left-truncation is caused by delayed entry of the individuals to the study. The most
common case of left-truncation is the retirees taking retirement from the age of 60+ and
their age is recorded at that point. However, there are individuals that died before they
retired and did not make it to the retirement. This type of incomplete observation is called
left-truncation (71). The survival of the individuals is conditional on the survival up to
point of the study entry.
The right truncation happens when the selection process of the study stops at some point.
For example, if a study deals with people who got infected within a specific time period,
there is a lack of observation for infections past this specific time period. This lack of
observation is considered to be right-truncated (71).
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1.2.3 Non-Parametric Methods of Survival Analysis
The main characteristic of the non-parametric methods is that no explicit assumptions are
made about the distribution of the survival times (20).
1.2.3.1 Kaplan-Meier Product Limit Estimator The most common tool for non-
parametric survival analysis is the Kaplan-Meier product limit estimator, which was sug-
gested by Kaplan and Meier (1958) (69).
If there are p distinct survival time observations, they are put in ascending order t1, t2, ..., tp.
Let nti be the number of individuals at risk at each ti and let dti be the number of individuals
who died, at each ti, where i = 1, 2, ..., p. The Kaplan-Meier estimator of the survival
function is (71) (69):
Sˆ(t) =
∏
ti≤t(1−
dti
nti
), t ≥ 0. (8)
At the start of each study i.e. at t0, dt0 = 0, and the estimator is equal to one.
1.2.4 Semi-Parametric Methods of Survival Analysis
A popular statistical method used for semi-parametric survival analysis is the Cox propor-
tional hazards model, suggested by Cox (1972) (24). This is a regression modelling the
hazard as:
h(t, x, β) = h0(t) exp {xβ}, (9)
where h0(t) is the baseline hazard, x denotes a vector of covariates and β the vector of
regression coefficients, linking the covariates to the hazard function.
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The proportional hazards model leaves the baseline hazard undefined, but it assumes that
the ratio of the hazards is constant over time i.e. does not depend on time (63).
To analyse the proportional hazards model, Cox (1972) (24), suggested the partial likeli-
hood function:
Lp(β) =
n∏
i=1
[
exp {xiβ}∑
j∈R(ti) exp {xjβ}
]δi , (10)
where δi is the censoring indicator and the summation in the denominator is over all
subjects in the set of risk (R(ti)) at time ti. (10) assumes that there are no tied times.
Breslow (1974) (14) and Efron (1977) (35) suggested approximations for the partial likeli-
hood function, taking into account tied times. These are:
Lp1(β) =
n∏
i=1
[
exp
{
x(i)+β
}
[
∑
j∈R(ti) exp {xjβ}]δi
] (11)
and
Lp2(β) =
n∏
i=1
[
exp
{
x(i)+β
}∏di
k=1 [
∑
j∈R(t(i)) exp {xjβ} − k−1di
∑
j∈D(t(i)) exp {xjβ}]
]. (12)
respectively. di denotes the number of subjects with survival time t(i), x(i)+ is equal to the
sum of the covariate values over the di subjects and D(t(i)) denotes the individuals that
have survival times equal to t(i).
Despite Cox proportional hazards model’s popularity, its proportionality assumption often
fails to be satisfied. Thus, there is a need for other models that do not use so strong
assumptions.
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1.2.5 Parametric Methods of Survival Analysis
Parametric methods make use of the assumption that the survival times come from a spe-
cific distribution (20) (71) (63). The main distributions used are: Exponential, Weibull,
Log-Logistic, Log-Normal, Extreme Value and Logistic. Additionally, Gompertz, Perks,
Beard, Makeham, Makeham-Perks and Makeham-Beard distributions, are popular on ac-
tuarial applications and mostly used for the cases of left-truncation and right-censoring.
These models are widely popular, especially in actuarial applications. The reasons for this
popularity are that the effect of the variables on survival time is modelled explicitly, that
full likelihood is used and that different shapes of the hazard are allowed.
In case of right-censoring the likelihood is given by (9) (20) (21) (63) (71):
L(θ, δi; ti) =
n∏
i=1
{f(ti; θ)}δi {S(ti; θ)}1−δi , (13)
or equivalently it can be also given by (138):
L(θ, δi; ti) =
n∏
i=1
{h(ti; θ)}δi {S(ti; θ)}, (14)
where n is the number of individuals, θ denotes all the parameters that need to be esti-
mated, ti is the follow-up time of the i
th individual and δi is the censoring indicator of the
irh individual.
In case that left-truncation is present in the data, along with right-censoring, all proba-
bilities are changed to conditional ones. To be specific, if the truncation time for the ith
individual is denoted by Ai, the probability density and survival function are replaced by
f(ti;θ)
S(Ai;θ)
and S(ti;θ)
S(Ai;θ)
respectively (71).
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Therefore, for left-truncation and right-censoring, the likelihood changes to (71):
L(θ, δi; ti) =
n∏
i=1
(
f(ti; θ)
S(Ai; θ)
)δi(
S(ti; θ)
S(Ai; θ)
)1−δi . (15)
The difference between the two likelihoods (13) and (15), is that the left-truncated and
right-censored likelihood is divided by the survival functions of the truncation times.
1.2.5.1 Weibull Distribution Weibull and Stockholm (1951) (146) suggested the use
of Weibull distribution. The hazard, cummulative hazard, survival and probability density
function of the Weibull distribution are given by (71) (92):
h(t;σ, γ) = γσ−1(tσ−1)γ−1, (16)
H(t;σ, γ) = (tσ−1)γ, (17)
S(t;σ, γ) = exp
{−(tσ−1)γ}, (18)
and
f(t;σ, γ) = γσ−1(tσ−1)γ−1 exp
{−(tσ−1)γ}, (19)
respectively. σ > 0 and γ > 0 are the distribution parameters, scale and shape, respectively,
and t is the follow-up time. Weibull is only defined for t ≥ 0. When γ = 1, the Weibull
distribution becomes Exponential distribution (87), which is a special case of it. The
hazard function (16) becomes
h(t;σ) = σ−1, (20)
i.e. h(t) is constant over time.
Weibull data can be modelled both parametrically, and semi-parametrically. This is due
to the fact that the Weibull distribution has the property of the proportional hazards i.e.
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the Weibull hazard function can take the form
h(t, x, β) = h0(t) exp {xβ}, (21)
where h0(t) is the baseline hazard, x denotes a vector of covariates and β the vector of
regression coefficients, linking the covariates to the hazard function. Setting λ = σ−γ
and λ = exp(β0 + βx), (16) becomes h(t, x, β) = γt
γ−1 exp(β0) exp(βx), where h0(t) =
γtγ−1 exp(β0)
The proportional hazards model leaves the baseline hazard undefined, but it assumes that
the ratio of the hazards is constant over time i.e. does not depend on time (63). However,
parametric methods have other advantages like making use of the assumption that the
survival times come from a specific distribution (20) (71) (63), the effect of the variables
on survival time is modelled explicitly, that full likelihood is used and that different shapes
of the hazard are allowed.
1.2.5.2 Log-Logistic Distribution The hazard, cummulative hazard, survival and
probability density functions of the Log-Logistic distribution are given by (13) (63) (71):
h(t;λ, p) = λptp−1(1 + λtp)−1, (22)
H(t;λ, p) = log[1 + λtp], (23)
S(t;λ, p) = (1 + λtp)−1, (24)
and
f(t;λ, p) = (λptp−1)(1 + λtp)−2, (25)
respectively. λ > 0 and p > 0 are the distribution parameters, scale and shape, respectively.
It is only defined for t ≥ 0.
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1.2.5.3 Log-Normal Distribution The hazard, cummulative hazard, survival and
probability density function of the Log-Normal distribution are given by (40) (63) (71):
h(t;µ, σ) = exp
{−(log {t} − µ)22−1σ−2}t−1σ−1(2pi)− 12 {1− Φ[log t− µ
σ
]
}−1
, (26)
H(t;µ, σ) = − log {1− Φ[(log t− µ)σ−1]}, (27)
S(t;µ, σ) = 1− Φ[(log {t} − µ)σ−1], (28)
and
f(t;µ, σ) = exp
{−(log {t} − µ)22−1σ−2}(tσ)−1(2pi)− 12 , (29)
respectively. µ ∈ < and σ > 0 are the distribution parameters, location and scale respec-
tively. Φ(z) is the cummulative distribution function of the standard normal distribution
(71).
1.2.5.4 Extreme Value Distribution The hazard, cummulative hazard, survival and
probability density function of the Extreme distribution, are given by (81) (106) (148):
h(t;µ, σ) = σ−1 exp
{
(t− µ)σ−1}, (30)
H(t;µ, σ) = exp
{
(t− µ)σ−1} , (31)
S(t;µ, σ) = exp
{− exp{(t− µ)σ−1}} (32)
and
f(t;µ, σ) = σ−1 exp
{
(t− µ)σ−1 − exp{(t− µ)σ−1}} , (33)
respectively. µ ∈ < and σ > 0 are the distribution parameters, location and scale respec-
tively. t is defined from −∞ to ∞. We deal with log-Extreme Value, which is essentially
Weibull, see above for the Weibull.
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1.2.5.5 Logistic Distribution The hazard, cummulative hazard, survival and prob-
ability density functions of the Logistic distribution are given by (106) (148):
h(t;µ, σ) = σ−1 exp
{
(t− µ)σ−1} [1 + exp{(t− µ)σ−1}]−1, (34)
H(t;µ, σ) = log[1 + exp
{
(t− µ)σ−1}], (35)
S(t;µ, σ) = [1 + exp
{
(t− µ)σ−1}]−1 (36)
and
f(t;µ, σ) = σ−1 exp
{
(t− µ)σ−1} [1 + exp{(t− µ)σ−1}]−2, (37)
respectively. µ ∈ < and σ > 0 are the distribution parameters, location and scale respec-
tively. t is defined from −∞ to ∞. We deal with Log-Logistic, which is only defined for
t ≥ 0.
Log-Logistic is a survival distribution, but Logistic is not.
1.2.5.6 Gompertz Distribution Benjamin Gompertz, a British actuary, introduced
a law of mortality (48), which is nowadays called the Gompertz law of mortality (22)
(86). He assumed the exponential increase of mortality with age. The hazard function and
cummulative hazard function of the Gompertz law are (106) (107) (71):
h(t) = t exp(at) (38)
and
H(t) = −ta−1[1− exp (at)], (39)
respectively. t the follow-up time and a > 0 are the distribution parameters. The survival
function is given by:
S(t) = exp (ta−1[1− exp(at)]). (40)
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1.2.5.7 Perks Distribution Perks (1932) (98) found empirically that the mortality
could be approximated by a logistic curve. The hazard function, cummulative hazard
function and survival function for the Perks mortality law are given by (106) (107):
hx(t) =
exp {a+ bx}
1 + exp {a+ bx} , (41)
Hx(t) = b
−1 log
{
1 + exp {a+ b(x+ t)}
1 + exp {a+ bx}
}
(42)
and
Sx(t) =
{
1 + exp {a+ b(x+ t)}
1 + exp {a+ bx}
}−b−1
, (43)
respectively, where a, b ∈ <.
1.2.5.8 Beard Distribution Beard (1959) (10) added to Perks distribution (1932)
(98) a heterogeneity parameter ρ. The hazard, cummulative hazard and survival function
of the Beard mortality law are given by:
hx(t) =
exp {a+ bx}
1 + exp {a+ ρ+ bx} , (44)
Hx(t) = exp {−ρ}b−1 log
{
1 + exp {a+ ρ+ b(x+ t)}
1 + exp {a+ ρ+ bx}
}
(45)
and
Sx(t) =
{
1 + exp {a+ ρ+ b(x+ t)}
1 + exp {a+ ρ+ bx}
}− exp {−ρ}b−1
, (46)
respectively, where a, b ∈ <.
1.2.5.9 Makeham Distribution Makeham (1859) (84) found that Gompertz’s law
could be improved by adding a constant term. The hazard, cummulative hazard and
survival function are given by (106) (107):
hx(t) = exp {}+ exp {a+ bx}, (47)
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Hx(t) = t exp {}+ b−1(exp {bt} − 1) exp {a+ bx} (48)
and
Sx(t) = exp
{−[t exp {}+ b−1(exp {bt} − 1) exp {a+ bx}]}, (49)
where a, b,  ∈ <.
1.2.5.10 Makeham-Perks Distribution Makeham-Perks distribution was empiri-
cally derived by Perks (1932) (98). Using Richards (2008) (106) and Richards (2011)
(107) notation, the hazard, cummulative hazard and survival function are given by:
hx(t) =
exp {}+ exp {a+ bx}
1 + exp {a+ bx} , (50)
Hx(t) = t exp {}+ (1− exp {})b−1 log
{
1 + exp {a+ b(x+ t)}
1 + exp {a+ bx}
}
(51)
and
Sx(t) = exp {−t exp {}}
{
1 + exp {a+ b(x+ t)}
1 + exp {a+ bx}
}(1−exp {})b−1
, (52)
where a, b,  ∈ <.
1.2.5.11 Makeham-Beard Distribution Makeham-Beard distribution was found em-
pirically by Perks (1932) (98). Using Richards (2008) (106) and Richards (2011) (107)
notation, the hazard, cummulative hazard and survival function are given by:
hx(t) =
exp {}+ exp {a+ bx}
1 + exp {a+ ρ+ bx} , (53)
Hx(t) = t exp {}+ (exp {−ρ} − exp {})b−1 log
{
1 + exp {a+ ρ+ b(x+ t)}
1 + exp {a+ ρ+ bx}
}
(54)
and
Sx(t) = exp {−t exp {}}
{
1 + exp {a+ ρ+ b(x+ t)}
1 + exp {a+ ρ+ bx}
}(exp {−ρ}−exp {})b−1
, (55)
where a, b, ρ,  ∈ <.
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1.2.6 Maximum Likelihood Estimation
Let n be the number of subjects. If t1, t2, ..., tn is a set of independent observations with
probability density function fi(ti; θ), where θ is a vector of J parameters, i = 1, 2, ..., n,
the likelihood function is defined as (145):
L(θ; t1, t2, ...tn) =
n∏
i=1
f(ti; θ). (56)
However, the log-likelihood function is easier to use due to the properties of the logarithms.
l(θ; t1, t2, ..., tn) = logL(θ; t1, t2, ...tn). (57)
In maximum likelihood estimation, the aim is to obtain the value of the estimates that
maximize the log-likelihood. This is done by differentiating the log-likelihood with respect
to each parameter, setting the derivative equal to zero and solving the resulting equation,
in order to obtain the maximum likelihood estimate θˆ (78):
∂l(θˆ;t)
∂θj
= 0, j = 1, ..., J. (58)
In the above equations l(θ; t) denotes the log-likelihood, t is the set of times t = {t1, t2, ..., tn}
for the individuals, θ is the set of θj parameters, θ = {θ1, θ2, ..., θJ}.
The Hessian matrix is given by (63):
H[l(θ; y)] =

∂2l(θ;t)
∂θ21
∂2l(θ;t)
∂θ1 ∂θ2
· · · ∂2l(θ;t)
∂θ1 ∂θj
∂2l(θ;t)
∂θ2 ∂θ1
∂2l(θ;t)
∂θ22
· · · ∂2l(θ;t)
∂θ2 ∂θj
...
...
. . .
...
∂2l(θ;t)
∂θj ∂θ1
∂2l(θ;t)
∂θj ∂θ2
· · · ∂2l(θ;t)
∂θ2j

. (59)
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The information matrix is (31):
I(θˆ) = −E[H[l(θ; y)]] (60)
and the approximation of variance-covariance matrix is the inverse of the information
matrix (8) (123): ̂
V ar(θˆ) = I−1(θˆ). (61)
1.2.7 Diagnostics for Survival Analysis Models
When a model is fitted to a data, certain assumption are made. Before making any
conclusions from the model fitted, it is crucial to ensure that all the model assumptions
made are valid. In case that assumption violations do occur, then the model may provide
faulty conclusions. Thus, it is extremely important to perform the appropriate model
diagnostics.
1.2.7.1 Cox-Snell Residuals The Cox-Snell residuals are used for assessing the over-
all fit of the model (127). They are defined as (73) (127):
cˆi = Hˆ(ti) = − log Sˆ(ti), (62)
where Sˆ is the estimated survival function. After evaluating the Cox-Snell residuals, they
can define time and censoring indicator can define the events (63). Using them, Kaplan-
Meier estimator is obtained and from that the estimated cummulative hazard function of
the Cox-Snell residuals (71). If the latter is plotted against the Cox-Snell residuals, the
overall fit can be seen. If the values obtained are approximately forming a straight line
that passes through the origin and has gradient equal to one, then the model is considered
to be adequate (73) (89).
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1.2.7.2 Martingale Residuals The martingale residuals are a modification of the
Cox-Snell residuals and are defined as (63):
Mˆi = δi − cˆi, (63)
where δi is the event indicator (71). Large martingale values indicate a poor fit of the
model for these points (41).
1.2.7.3 Deviance Residuals The deviance residuals are defined as (71) (32) (23)
Di = (Mˆi)
√
(−2(Mˆi + δi log(δi − Mˆi))), (64)
(Mˆi) in (64) is the signum function which is defined as follows (55):
(x) =

−1 if x < 0,
0 if x = 0,
1 if x > 0.
. (65)
The distribution of the deviance residuals is symmetric around zero (121) due to the
logarithm in the definition and thus, they are easier to work with than the martingale
residuals which can take values from −∞ to +1 (71) (32) (23). Generally, the deviance
residuals identify the individuals fitted inadequately by the model (121).
1.2.7.4 Score Residuals The score residuals identify which subjects are highly affect-
ing the estimation of the model (121) and they are defined as (63):
∂l(θˆ; t)
∂θj
=
n∑
i=1
L̂ij, (66)
where t is the set of ti values for i = 1, 2, ..., n, θ is the set of θj, where j = 1, 2, ..., J , pa-
rameters to be estimated. The vector of the score residuals of the ith subject corresponding
to θ parameters is denoted as Lˆi = (lˆi1, lˆi2, ..., lˆiθj) (63).
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Each score equation that contributes to the sum in (66), is in fact a re-weighted Schoenfeld
residual (62).
1.2.7.5 Scaled Score Residuals The scaled score residuals are (63):
Lˆ′i = ̂V ar(θ)Lˆi. (67)
The scaled score residuals measure how influential an observation is, in terms of parameter
estimation (scaled version of the score residuals (63)) (37).
1.2.7.6 Cook’s Distance Cook’s distance is the influence that a subject may have on
the estimation of the coefficients (83) and it can be evaluated using the score and scaled
score residuals (63):
ldi = LˆiLˆ
′
i. (68)
1.3 Longitudinal Analysis
Longitudinal data consists of repeated observations (126) on the same individual. This data
is typically highly unbalanced due to the difference in number and timing of observations
for each individual (139). This is because the conditions for each measurement cannot be
fully controlled.
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1.3.1 Linear Mixed Models
Laird and Ware (1982) (72) suggested a linear model for longitudinal data which includes
the within-person and the between-person variation.
Let n be the number of individuals and mi denote the number of observations for the i
th
individual, where i = 1, 2, ..., n. Let Yi be a mi×1 vector of responses for the ith individual.
Let a denote a p× 1 vector of unknown population parameters, Xi denote a known mi× p
design matrix linking a to Yi, bi be a k × 1 vector of unknown random individual effects
and Zi be a known mi × k design matrix linking bi to Yi.
For each individual i the model states that,
Yi = Xia+ Zibi + ei, (69)
where the errors ei are assumed to be independent and normally distributed N(0, Ri) (88)
i.e. they have mean zero and mi × mi covariance matrix Ri (139). The covariance is a
positive-definite matrix that depends on i, via its dimension mi.
The random effects bi ∼ N(0, D), where D is a k × k positive-definite covariance matrix
(139) and are assumed to be independent of each other and of the errors ei. The population
parameters a are treated as fixed effects.
Conditionally on random effects bi, Yi ∼ N(Xia+ Zibi, Ri) (139).
Marginally, yi ∼ N(Xia,Ri+ZiDZTi ) (139). The model can be simplified when the random
effects bi are independent i.e. Ri = σ
2I, where I is a mi ×mi identity matrix. Then, the
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marginal density function of Yi is (139):
f(yi) =
∫
f(yi|bi)f(bi) dbi , (70)
where f(yi|bi) and f(bi) are the density functions of Yi conditional on bi and bi respectively.
In order to fit the model and obtain the model parameters, maximum likelihood or re-
stricted maximum likelihood estimation can be used (139).
1.3.2 Missing Data Mechanisms
Little and Rubin (1987) (80) and Diggle and Kenward (1994) (33) classified the missingness
mechanisms for longitudinal measurements into three categories. These are:
1. MCAR- Missing Completely At Random: this happens when the probability of miss-
ing does not depend on observed or unobserved measurements.
2. MAR- Missing At Random: appears when the probability of missing depends on
observed measurements, but not on the unobserved ones.
3. MNAR- Missing Not At Random: arises when the probability of missing data depends
on observed and unobserved measurements.
If the drop-out (missing data) is present in the data, then ignoring the relationship be-
tween the drop-out and the response, is inappropriate (33). Hogan and Laird (1997b) (60)
concluded that when the missing observations are not missing at random, then the missing
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data has to be modelled with the longitudinal data, so that the estimates will be valid and
not biased.
1.4 Joint Analysis of Longitudinal and Survival Data
Longitudinal data include the set of repeated measurements, and survival data includes
the set of times until the event of interest, for the same patients. These two data subsets
were analyzed separately in the past, until it was realised that the longitudinal data can
be associated with the survival data (88).
A biomarker is a biological characteristic (e.g. molecule) which is used to identify a patho-
logical or physiological process (e.g. disease) (125). Biomarkers are often measured over
time and referred to as longitudinal biomarkers. They may affect survival.
The simple version of longitudinal data for joint modelling is to have one longitudinal
biomarker. There are however, more complicated scenarios where there are multiple longi-
tudinal biomarkers. Models that can handle different types of failing are called competing
risks models. These different types of failing can also be considered as informative censor-
ing. Multiple longitudinal biomarkers and competing risks models are briefly discussed in
Chapter 6.
For the simple joint modelling with only one biomarker and without any competing risks,
the first naive approaches to estimate the parameters were the last value carried forward
which is known to cause large bias, Prentice (1982) (101), and the two-stage procedure, Self
and Pawitan (1992) (118). A modern alternative is the simultaneous parameter estimation
for both processes, longitudinal and survival, which is now widely used. Different modelling
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strategies are used depending on the primary interest of the study (126).
1.4.1 Two-Stage Approach
The two-stage approach consists of estimating the longitudinal component first and then
substituting them to estimate the survival component. Tsiatis et al (1995) (135) and Albert
and Shih (2010) (4) use this approach with some variations.
Tsiatis et al (1995) (135) estimate the longitudinal components using repeated measures
random component model in the first stage. In the second stage, they estimate the pa-
rameters of a Cox proportional hazards model, using empirical Bayes estimates as in Dafni
and Tsiatis (1994) (28) and Laird and Ware (1982) (72).
Albert and Shih (2010) (4) used the two-stage approach for discrete time-to-event data.
First, they estimated the longitudinal components, then simulated the data from the lon-
gitudinal component and re-fitted the model. They related the longitudinal component to
the survival time, using a probit model. The simulation is performed to minimize bias due
to informative drop out.
The two stage approach however does not perform as well as the simultaneous parameter
estimation (129).
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1.4.2 Simultaneous Joint Modelling
The simultaneous parameter estimation, using a joint likelihood approach has become
popular due to an increased accuracy of estimation (129). The joint modelling paradigm
includes different modelling strategies such as pattern-mixture and selection models (126).
These can be extended by incorporating random effects and they are called random pattern-
mixture, random selection and an additional category called random effects models. There
are some differences in the definitions for each type of model and some overlaps between
them. For more details see Little (1995) (79), Hogan and Laird (1997b) (60), Sousa (2011)
(126) and McCrink (2013) (88).
Simple, yet detailed explanation used by Sousa (2011) (126) and McCrink (2013) (88)
for different joint modelling strategies is shown below. Let Y, T and B represent the
longitudinal, time-to-event and random effects parts.
Selection models: [Y, T,B] = [B][Y |B][T |Y ].
Pattern-Mixture models: [Y, T,B] = [B][T |B][Y |T ].
Random effects models: [Y, T,B] = [B][Y |B][T |B].
Due to a better performance of the simultaneous joint modelling compared to the other
methods such as last value carried forward or two-stage approach, this is the class of meth-
ods developed in this thesis. The primary interest is random effects (or shared parameter)
models.
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1.4.3 Pattern Mixture Models
In pattern mixture models, the main interest is centered on the longitudinal component
(126).
Wu and Bailey (1989) (149) were the first to consider a pattern-mixture model, under
informative missingness. They used a linear random effects model for the longitudinal
variable and the random effects were conditional on the event time.
Hogan and Laird (1997a) (59) described a mixture model for longitudinal and time-to-event
data. They assumed that the data is missing at random (unlike Wu and Bailey (1989)),
and that the individuals are subject to right-censoring. The longitudinal component is
modelled using a linear mixed effects model and they made no parametric assumptions
for the time-to-event distribution. Instead they estimate multinomial probabilities with
incomplete data for the survival component, as suggested by Cox and Oakes (1984) (25).
1.4.4 Selection Models
In selection models, the primary interest is the time-to-event component with the longi-
tudinal component most commonly modelled by a linear mixed effects model (126). The
time-to-event component is modelled using either a Cox proportional hazards or a probit
model.
Brown et al.(2005) (17) used a proportional hazards model for the survival component.
However, they proposed a cubic B-spline, instead of a linear mixed effects model, to model
the longitudinal data. Instead of making assumptions about the behaviour of the longi-
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tudinal component over time, they use cubic B-splines for greater flexibility. They also
extended the model to accomodate multiple longitudinal response variables.
1.4.5 Random Effects Models
In random effects models (also called shared parameter models) the two processes, longi-
tudinal and time-to-event, are linked through shared random effects, i.e. they are condi-
tionally independent given the random effects. (88) (126).
Wu and Carroll (1988) (150) suggested a linear random effects model for two-treatment
group data when informative censoring is present. They assumed that missingness pro-
cess and staggered entry are non-informative and independent of right-censoring. The
probability of being right-censored is given by a probit model conditional on the random
effects.
Follmann and Wu (1995) (45) suggested a shared parameter joint model, which is a gen-
eralization of the model suggested by Wu and Carroll (1988) (150). Suppose Yi are the
longitudinal measurements for the ith subject and Ti the time-to-event for the i
th subject.
These are linked with a set of shared random effects bi, which follow a distribution with
mean zero and distribution function H(·).
The longitudinal value conditional on the random effects follows a generalized linear model:
ψ[E(yij|bi)] = awij + bizij, (71)
where ψ(·) is the link function, wij and zij are the vectors of covariates. Additionally,
it is assumed that the time-to-drop-out conditional on the random effects also follows a
generalized linear model.
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The full joint shared parameter model is:
f(Yi, Ti) =
∫
gYi(Yi|bi)gTi(Ti|bi) dH(bi) , (72)
where gYi(Yi|bi) and gTi(Ti|bi) are the conditional models and H(bi) is the distribution
function of the bi. Follmann and Wu (1995) showed that this model does not require the
data to be MAR or MCAR.
DeGruttola and Tu (1994) (30) proposed an extension of the model suggested by Wu
and Carroll (1988) (150) i.e. a model that has a more general random effect structure,
rather than two random effects only. The longitudinal component is modelled using a
more general linear random effects model and random effects follow a multivariate normal
distribution. Censoring of survival time is assumed to be non-informative. Specifically, the
probability of being censored is independent of the unobserved failure time. Additionally,
missing observations are missing at random. The relationship between the longitudinal
component and survival component is modelled via linear or nonlinear regression, e.g. Cox
proportional hazards model.
Faucett and Thomas (1996) (42) and Wulfsohn and Tsiatis (1997) (151) introduced a
random effects model with proportional hazards. The parameters are estimated by using
MCMC method of Gibbs sampling by Faucett and Thomas (1996) (42), while Wulfsohn
and Tsiatis (1997) (151) introduce an EM algorithm.
The two most common submodels used for shared parameter models are, for longitudinal
component
Yij = β0i + β1itij + ij, (73)
where Wi(tij) = β0i + β1itij is the true unobserved longitudinal value for the i
th individual
at the jth time-point, while Yij are the observed longitudinal measurements. Errors ij ∼
N(0, σ2e) while β0i and β1i have a bivariate normal distribution with means µβ0 and µβ1
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and the covariance matrix Σ =
[
σ2β0 σβ0β1
σβ0β1 σ
2
β1
]
, where σβ0β1 = ρσβ0σβ1 with ρ being the
correlation between the random effects. For survival component,
λi(t) = λ0(t)e
α(β0i+β1itij), (74)
where α is the association between the longitudinal and the survival component. Addi-
tionaly, Wulfsohn and Tsiatis (1997) (151) discuss the two-stage modelling, which was
suggested in Tsiatis, De Gruttola and Wulfsohn (1995) (135). Two-stage modelling was
performed by first fitting a model to longitudinal measurements and then estimating the
Cox model by substituting the empirical Bayesian estimates by Laird and Ware (1982)
(72). This approach does not take into account the survival information, while fitting
the longitudinal model and therefore, it cannot be more efficient than performing a direct
maximization.
Henderson et al (2000) (56) extended the model used by Faucett and Thomas (1996) (42)
and Wulfsohn and Tsiatis (1997) (151). They do not use the same Wi(tij), instead they
used
W
′
i (tij) = γ1U0i + γ2U1itij + γ3(U0i + U1itij) + U2i, (75)
where U2i ∼ N(0, σ2U2) is independent of (U0i, U1i), while the rest remain the same as in
Wulfsohn and Tsiatis (1997) (151). γ1 and γ2 measure the association between W
′
i (tij) and
Wi(tij) through intercept and slope, while U2i models frailty. They also suggest a Monte
Carlo method for evaluating the likelihood integral for the reduction of the variance.
This type of model has as special case the model considered by Laird and Ware (1982)
(72). By extending that model, Henderson et al (2000) (56) consider more situations where
an association between longitudinal and survival component may exist. Henderson et al.
(2000) (56) assume that the time, in which the measurements are taken, is non-informative
and that censoring is also non-informative.
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Other shared parameter models considered in the literature had different characteristics.
Wang and Taylor (2001) (144) use a longitudinal model for continuous data and a pro-
portional hazards model, which includes the longitudinal biomarker (as a time-dependent
variable) and other covariates for survival component. The longitudinal model contained
fixed and random effects, independent measurement error and an integrated Ornstein-
Uhlenbeck (IOU) stochastic process. They use Bayesian techniques in order to fit the
model. Their simulation results indicate that the method gives quite accurate estimates,
except for the parameter of the IOU, for which they assume that it is due to a very skewed
distribution of the parameter.
1.4.6 Integral Approximation and Parameter Estimation
Maximum likelihood is among the first estimation techiniques used for the joint model
(88) (120). Expectation-Maximization (EM) algorithm is another popular algorithm that
is often implemented (29) (88). It treats the random effects as missing data, see Wulfsohn
and Tsiatis (1997) (151).
Joint modelling likelihood includes integrals that cannot be solved analytically. The main
difficulty in joint modelling is the numerical integration with respect to the random effects.
Thus numerical approximations are widely used, such as Gauss-Hermite rule and its adap-
tations (88). This is used by Wulfsohn and Tsiatis (1997) (151), Henderson et al.(2000)
(56), Song et al.(2002) (124) and Rizopoulos et al.(2008) (108). However, when the di-
mension of the random effects increases, the computational complexity of the Gaussian
Quadrature increases exponentially. Rizopoulos (2012) (113) suggest to use a pseudo-
adaptive Gauss-Hermite Quadrature rule. Specifically, this is achieved, by first fitting the
mixed effects model for the longitudinal component and extracting information about the
location and the scale of the posterior distribution of the random effects. There is an issue,
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though, with the quadrature points’ location with respect to the main mass of the inte-
grand’s location and integrand spread may differ from the spread of the weight function. In
this case, even for large number of quadrature points, the approximation is poor and this is
due to the fact that quadrature is not located where the most of the mass of the integrand
is. Thus, by centering and scaling the integrand in order to make the weight-function
proportional to the density function, fewer quadrature points are required.
The centering and scaling are achieved using the location of the mode bˆi and the second
order derivative matrix Hˆi for each subject. So, after fitting the linear mixed effects model,
the empirical Bayes estimates of b˜i and H˜
−1
i are extracted and used in the transformation
r˜t = b˜i+
√
2B˜−1bt, where B˜i denotes the Cholesky factor of H˜i and bt denote the absciccas.
As the number of observations for each individual increases, it is sufficient to use the
information from the mixed effects model, i.e. the maximum likelihood estimates for the
joint model will be close to the maximum likelihood estimates of the linear mixed model.
Thus, this procedure is only required to be implemented once, at the start of optimization,
and not at every quadrature point like the adaptive Gauss-Hermite rule. So, there is
no need for computational relocation at each iteration. Using simulations, Rizopoulos
(2012) (113) found that this pseudo-adaptive quadrature rule performs well, even when
the number of observations is quite small.
Laplace Approximations are also used to make the computational approach easier (88).
Rizopoulos et al.(2009) (109) suggest a new computational approach which requires fewer
repetitions than the often used Monte Carlo and Gaussian Quadrature. For these the
amount of time needed for the integral evaluation increases as the dimensions of the in-
tegral increase. Thus, they use the Laplace approximation for integrals and develop an
EM algorithm for the estimates. This is made under the assumption that censoring and
visiting processes (for the longitudinal measurements) are non-informative i.e. that they
are independent of the random effects, survival time and longitudinal measurement, similar
to Tsiatis and Davidian (2004) (134).
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Bayesian methods are also used to estimate parameters. Faucett and Thomas (1996) (42)
used a Markov Chain Monte Carlo (MCMC), while other authors use MCMC algorithm
with a Gibbs sampler, Faucett et al.(2002) (43), Xu and Zeger (2001) (152), Brown et
al.(2005) (17), Guo and Carlin (2004) (51).
Hsieh, Tseng and Wang (2006) (64) suggest bootstrapping for the estimation of standard
errors, while they notice that the EM estimates given in Wulfsohn and Tsiatis (1997) (151)
are efficient and robust as long as the longitudinal data contains a lot of information (i.e.
not have large measurement errors or are not too dispersed).
Sweeting and Thompson (2011) (129) have given a comparison of maximum likelihood
and Bayesian estimation of the joint modelling and concluded that despite the computa-
tional advantages of Bayesian approaches, the need to choose prior distributions requires
a sensitivity analysis.
Further estimation techniques include the conditional score approach proposed by Tsiatis
and Davidian (2001) (133) and the Dimension Reduction Method by Bianconcini (2015)
(12).
This thesis will work with Gauss-Hermite approximation and maximum likelihood estima-
tion will be used because Bayesian approaches depend on a prior and require a sensitivity
analysis, Sweeting and Thompson (2011) (129). Besides maximum likelihood, bootstrap-
ping will also be used for the estimation of the parameters and their standard errors.
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1.4.7 Accelerated Failure Time Models
Despite Cox proportional hazards model’s popularity in conjuction with joint modelling,
its proportionality assumption often fails to be satisfied. Thus, there is a need for other
models that do not use this assumption. Parametric models make use of the assumption
that the survival times come from a specific distribution (20) (71) (63).
Accelerated failure time models are the models that are linearly-related with the log sur-
vival time (63). In this section, the joint models that use accelerated failure time models
for the survival sub-model are considered.
Pantazis et al. (2005) (95) suggested a bivariate linear mixed model for longitudinal
measurements and a log-normal model for time-to-event. Additionally, they assume that
the individual level random coefficients and survival residuals follow jointly a multivarite
normal distribution with zero mean. Pantazis and Touloumi (2007) (94) found that the
model suggested by Pantazis et al. (2005) (95) is quite robust, but the standard errors
may be underestimated, especially under heavily skewed distributions.
Vonesh et al. (2006) (142) proposed a shared random parameter model for the joint
distribution of longitudinal and time-to-event data. The submodels are generalized non-
linear mixed model for longitudinal and accelerated failure time model for the survival
data.
Tseng, Hsieh and Wang (2005) (132) proposed a joint modelling approach that includes
an accelerated failure time model for the survival submodel and a linear mixed model for
the longitudinal submodel. This can be used when the proportionality assumption of the
Cox model fails.
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A general parametric survival family including the accelerated failure time models is con-
sidered in this thesis.
1.4.8 Left-Truncated Survival Data
The majority of researchers working either with survival data on its own, or in joint mod-
elling, consider only right-censoring. Left-truncation is often neglected. However, if left-
truncation is not taken into account in joint modelling then subjects with shorter survival
times are excluded from the sample, and thus longitudinal measurements are sampled with
bias. An exclusion is the paper by Su and Wang (2012) (128), who suggested an approach
for joint modelling that overcomes the bias caused by left-truncation. They developed
an approach to left-truncated and right-censored survival data with longitudinal covari-
ates. For the longitudinal component, they use a linear mixed effects model, while for the
survival part they use a proportional hazards model.
The subject i is enrolled into a study only if the survival time is greater or equal to the
truncation time. They use the standard assumption that the survival time of the ith subject,
the truncation time of the ith subject and the difference between the censoring time and
truncation time for the ith individual are conditionally independent given the covariates,
which is equivalent to assuming conditional independence of survival time, truncation
time and the difference between truncation and censoring time, given the random effects.
Additionally, they assume that the survival time and the difference between truncation
time and censoring time are independent of the random effects.
They found that the full likelihood can be simplified to a conditional likelihood. Left-
truncation, though, makes score equations more complicated, and thus they use a modified
likelihood in order to simplify the estimation.
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This thesis will also use left-truncation since not taking it into account when fitting a
model, causes bias.
1.5 Summary
Joint Modelling is the simultaneous modelling of longitudinal and survival data. There are
two different factorizations for this type of modelling: pattern-mixture and selection models
(more details in Chapter 2). For both factorizations random effects can be incorporated
resulting in random pattern-mixture and random selection models. Additionally there is
another category of models, random effects models (or shared parameter models) in which
the longitudinal and survival submodels are independent conditional on the random effects.
This thesis considers a shared parameter model.
The two processes, longitudinal and time-to-event, can be analyzed separately, but the
association between them can be used to increase the efficiency of the joint analysis, aimed
at the evaluation of the effects of longitudinal covariates on the occurrence of the events.
The longitudinal covariates are typically observed in a set of patient-specific time-points
and can include missing values. Historically, the first, naive approaches were based on
the last value carried forward method which is known to cause substantial biases, and the
two-stage estimation procedure. A simultaneous parameter estimation for both processes,
longitudinal and survival is the widely used modern alternative. The modelling strategies
used in the joint modelling differ depending on the primary interest of the research. The
thesis primary interest is the association of the longitudinal component to the survival
time.
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Up to date, all published joint modelling models consider joint models for right-censoring
only, neglecting left-truncation. However, data often includes left-truncation which can
cause bias to estimates of the parameters, since the survival of the individuals in a study
is conditional on the survival up to the point of entry. This thesis considers not only
shared parameter model for right-censoring case, but also for the case of left-truncation
and right-censoring.
The majority of joint modelling literature considers Cox proportional hazards model for the
time-to-event data. The proportional hazards model leaves the baseline hazard undefined,
but it assumes that the hazard functions are multiplicatively related which means that
their ratio is constant over time. Despite Cox proportional hazards model’s popularity, its
proportionality assumption often fails to be satisfied. Thus, there is a need for alternative
models that do not use this assumption. Parametric methods assume that the survival
times come from a specific distribution. The main distributions used are: Weibull, Log-
Logistic, Log-Normal, Extreme Value, Logistic, Gompertz, Perks and Beard. These models
are widely popular, especially in actuarial applications. The reasons for their popularity
include the direct inference of the effect that the variables have on survival time, the use
of maximum likelihood estimation and the ability to incorporate different shapes of the
hazard.
Statistical inference in parametric modelling is mostly likelihood-based. The joint likeli-
hood is easy to write out but the integrals that are part of it cannot be solved analytically.
Approximations used include Gauss-Hermite approximation, Laplace approximation and
the Dimension Reduction Method. This thesis uses a Gauss-Hermite approximation for
the integral.
The estimation techniques include Bayesian methods based on Markov Chain Monte Carlo,
or frequentist methods such as conditional score approach, maximum likelihood, and max-
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imum likelihood with bootstrap estimation for standard errors. In this thesis maximum
likelihood estimation, bootstrap, and maximum likelihood estimation with bootstrap for
standard errors are used.
Reviews of joint modelling approaches for this field can be found in Tsiatis and Davidian
(2004) (134), Sousa (2011)(126) and McCrink et al (2013) (88). Software available in R
include the JM package (110) and the the joineR package, (99). The joint modelling soft-
ware is also available in stata (27), matlab (105), winBUGS and SAS, using the NLMixed
Procedure by (51).
Chapter 3 contains the main theoretical considerations of the thesis. It presents the joint
modelling framework, the sub-models and the log-likelihood for right-censoring and left-
truncation, describes the Gauss-Hermite and Laplace approximation that are applied to
the likelihood integral, and the maximum likelihood and the bootstrap estimation of the
parameters. Chapter 4 includes a simulation study for the joint modelling presented in
Chapter 3. Chapter 5 describes the applications of the developed methods to two medical
problems, prostate cancer and primary biliary cirrhosis (PBC) dataset from the JM package
(110). Chapter 6 presents the future extensions of the joint modelling approach presented
on Chapter 3.
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2 Joint Modelling of Longitudinal and Survival Data
2.1 Introduction
The previous chapter described joint modelling methods for longitudinal and survival data,
and also longitudinal and survival analysis separately. There was no research so far on left-
truncation and right-censoring joint modelling using parametric survival models and this
is what this chapter will describe.
First, the necessary notation is introduced, and then the linear mixed model that is used
for the longitudinal component and a general class of models for the survival component
are described. Then, the shared parameter likelihood for two cases, right-censoring and
right-censoring and left-truncation, is obtained. Due to the difficulty in evaluating the like-
lihood integral analytically, integral approximations are applied and a Weibull application
is described in detail. Finally, the methods of maximum likelihood and boostrap to obtain
the estimates of the parameters are explained.
2.2 Notation
Let Ai, T
∗
i and Ci denote the left-truncation time, true survival time and censoring time
respectively, for the ith individual, i = 1, ..., n. The observed survival time for the ith in-
dividual is given by Ti = min(T
∗
i , Ci). δi = I(T
∗
i ≤ Ci) is the censoring indicator (1-dead,
0-alive). Let ti = {tij, j = 1, 2, ...,mi}, be the set of mi time-points, at which the ith indi-
vidual is observed, these could differ for each individual, and Yi(ti) = {Yi(tij), j = 1, ...,mi}
be a vector of the observed values of a longitudinal biomarker.
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Xi(t), Zi(t) and Yi(t) are matrix functions of time t. These are not observed at all time-
points, but only at tij, j = {1, ...,mi}. Xi(ti), Zi(ti) are the matrices of the p fixed and q
random time-dependent covariates, respectively, with xTi (t), z
T
i (t) being their row vectors
at time t. Let Ui be the set of time-independent covariates for the i
th patient and uTi
be a row vector at all times t. Let MTi be the vector of the s time-independent survival
covariates, related only to survival.
2.3 Longitudinal Sub-Model
The subject-specific observed values of the longitudinal biomarker are
Yi(ti) = X
T
i (ti)β + Z
T
i (ti)bi + U
T
i λ+ ei(ti), (76)
((109),(139)) where β is a vector denoting time-dependent fixed effects, λ a vector de-
noting a time-independent fixed effects and bi a vector denoting the random effects for
the ith individual. ei(ti) is a mi × 1 vector of the measurement errors, independent of all
other variables. The errors are normally distributed N(0, σ2e) ((109),(139)) and correlation
between repeated measurements in longitudinal process is (ei(tij), ei(tij′)) = 0 for j 6= j′,
((109),(139)).
Assume that there are p time-dependent fixed parameters. Then β is p × 1 vector and
XTi (ti) is a mi× p design matrix for time-dependent fixed effects. Assuming there are q
random effects, bi is a q×1 vector, and ZTi (ti) is a mi× q design matrix for random effects.
The elements of bi ∼MVN(0, D) and D is a q× q variance-covariance matrix. If there are
r time-independent fixed parameters, λ is a r × 1 vector of time-independent fixed effects
that links a mi × r matrix, UTi , to the longitudinal observations Yi(ti).
The conditional expectation of Yi(ti) given bi, is denoted byWi(ti) = {Wi(tij), j = 1, ...,mi}.
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It is given by
E[Yi(ti)|bi] = Wi(ti) = XTi (ti)β + ZTi (ti)bi + UTi λ, (77)
((109),(139)), and thus the longitudinal biomarker is given by
Yi(ti) = Wi(ti) + ei(ti). (78)
2.4 Survival Sub-Model
Let h(t) be a function of time. Two important cases are
h(t) =
log(t), if accelerated failure time modelt, for the rest of the parametric models. (79)
For the ith individual h(t) can be written as
h(ti) = µi(ti) + σ × i, (80)
where σ is the scale parameter, i are the errors from the appropriate survival distribution
and µi(t) is given by
µi(t) = αWi(t) +M
T
i γ, (81)
((63),(90),(97)), where α is the univariate association parameter between the longitudinal
and the survival sub-models, ((109),(113)). When α = 0, there is no relation between the
two processes ((113),(109)). In equation (145), γ is the regression coefficient which links
the time-independent covariates, MTi . For s time-independent survival covariates, γ is s×1
vector of regression coefficients for 1 × s vector of time-independent survival covariates,
MTi .
Therefore, the joint model survival hi(t) for the i
th individual at an arbitrary time-point t
is given by
hi(t) = α[x
T
i (t)β + z
T
i (t)bi + u
T
i λ] +M
T
i γ + σ × i. (82)
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2.5 Likelihood for Joint Modelling
Censoring and drop-out mechanisms are assumed to be non-informative, i.e. independent
of the random effects, survival time and longitudinal measurements.
For a shared parameter model, the conditional independence assumption is needed ((113),(109)).
The two processes, longitudinal and survival, are assumed to be independent given the ran-
dom effects bi, i.e. the only association between them is induced by the random effects
((113),(109)).
2.5.1 Joint Modelling Parameterization
Let Y and T denote the longitudinal and survival component of the joint modelling likeli-
hood. To ease notation, let us not include any other quantities such as parameters.
The likelihood of observed response data is given by L(Y, T ) =
∫
L((Y, T )|b)L(b)db. Y and
T are both conditional on b.
Let us assume that b underlies both processes Y and T ie those two components are
independent conditional on b and so the full likelihood of a shared-random effects model
is given by L(Y, T ) =
∫
L(Y |b)L(T |b)L(b)db.
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2.5.2 Likelihood under Right-Censoring
The likelihood of the shared parameter model is defined by
L(Yi, Ti, δi; θ) =
∫
L(Yi|bi; (θy, σ2e))L(Ti, δi|bi; (θt, σ2))φq(bi;D)dbi, (83)
where φq(·;D) is the q-variate normal density with zero mean and the variance-covariance
matrix D, and L(·) denote the appropriate likelihood functions. θy = (β, λ) and θt =
(θy, γ, α).
Since the longitudinal measurements, Yi(tij), j = {1, ...,mi}, conditional on bi are inde-
pendent,
L(Yi|bi; (θy, σ2e)) =
∏mi
j=1 φ (Yi(tij);Wi(tij), σ
2
e) , (84)
where φ(·, µ, σ2) is the univariate Gaussian density with the mean µ and the variance σ2.
Denote f(·) and S(·) the probability density function and the survival function, respec-
tively, for the appropriate survival distribution. Then
L(Ti, δi|bi; (θt, σ2)) =
[
f(Ti|bi; θt, σ2)
]δi [S(Ti|bi; θt, σ2)]1−δi .
The joint likelihood contribution for right-censoring is given by
L(Yi, Ti, δi; θ) =
∏n
i=1
∫∞
−∞
∏mi
j=1 φ(Yi(tij);Wi(tij), σ
2
e)×
[f(Ti|bi; θt, σ2)]δi [S(Ti|bi; θt, σ2)]1−δi φq(bi;D) dbi
(85)
2.5.3 Likelihood under Left-Truncation and Right-Censoring
The same considerations apply for likelihood under left-truncation and right-censoring.
The only difference is that the survival part includes truncation times.
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Subjects are part of the study only if the survival time is greater or equal to the truncation,
i.e. the truncation time is the starting point and survival time will now be T ′i = Ti + Ai
for the ith subject, where Ai and Ti are the truncation and the un-adjusted survival time.
Survival time, truncation time and difference between censoring and truncation time are
conditionally independent given the covariates.
The likelihood of the shared parameter model is defined by
L(Yi, Ti, Ai, δi; θ) =
∫
L(Yi|bi; (θy, σ2e))L(Ti, Ai, δi|bi; (θt, σ2))φq(bi;D)dbi, (86)
where φq(·;D) is the q-variate normal density with zero mean and the variance-covariance
matrix D, and L(·) denote the appropriate likelihood functions.
Denote f(·) and S(·) the probability density function and the survival function, respec-
tively, for the appropriate survival distribution and T ′i = Ti + Ai. Then
L(Ti, Ai, δi|bi; (θt, σ2)) =
[
f(T ′i |bi; θt, σ2)
f(Ai|bi; θt, σ2)
]δi [S(T ′i |bi; θt, σ2)
S(Ai|bi; θt, σ2)
]1−δi
.
The joint likelihood contribution for left-truncation and right-censoring is given by
L(Yi, Ti, Ai, δi; θ) =
∏n
i=1
∫∞
−∞
∏mi
j=1 φ(Yi(tij);Wi(tij), σ
2
e)×[
f(T ′i |bi;θt,σ2)
f(Ai|bi;θt,σ2)
]δi [ S(T ′i |bi;θt,σ2)
S(Ai|bi;θt,σ2)
]1−δi
φq(bi;D) dbi
(87)
2.6 Approximations to Likelihood
The integrals for the likelihood of a shared parameter model (85) or (87) are complicated
and it is difficult to evaluate them analytically. Thus, an integral approximation is needed.
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Two possible approximations, Gauss-Hermite and Laplace approximation, are considered
in this section. The Gauss-Hermite approximation was used in our R program described
in the next Chapter.
2.6.1 Gauss-Hermite Approximation
For univariate integrals, the following relationship holds∫ ∞
−∞
f(x)exp(−x2)dx ≈
m∑
i=1
wif(xi), (88)
where the xi are zeros of the m
th order Hermite polynomial and wi are suitably corre-
sponding weights (82).
In the case where the integrals are multi-dimensional it is easier to expand around a single
mode. The variables should be transformed and centered at the mode and scaled by the
inverse of the second derivatives matrix, in order to center the quadrature rule near the
mode and to make variables’ scaling similar (50) (113) (137).
Suppose that the integral has the form
∫
RL
q(Θ) exp {h(Θ)} dΘ , where Θ is a L-dimensional.
Assuming that Θˆ is the mode of h, denote H = −∂
2h(Θˆ)
∂Θ∂Θ′ and let B
′
B = H be the Cholesky
factorization of H (50) (113) (137).
The Gauss-Hermite weight function is proportional to a N(0, 2−1I) density, and thus a
function that is proportional to that is preferred, in order to use a Gauss-Hermite rule.
Considering Θ as random quantity with log-density given by h(Θ), the first order normal
approximation to this distribution is the N(Θˆ, H−1) distribution. Parameterizing Θ as
A = 2−1/2B(Θ− Θˆ), the A variable has an approximate N(0, 2−1I) distribution (50) (113)
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(137).
Therefore, the integral becomes 2L/2|B|−1 ∫ exp(−A′A)f(A)dA, where
f(A) = q(21/2B−1A+Θˆ) exp[h(21/2B−1AΘˆ)+A
′
A]. The integral now can be approximated
using a Q-point Gauss-Hermite rule by 2L/2|B|−1∑Qq1=1 ωqLf(Ξql).
2.6.2 Gauss-Hermite Approximation to Likelihood Integral
The integrals in the likelihoods (85) and (87) have the form
∫
g(bi)φ(bi;D)dbi. They are
difficult to evaluate analytically, and a Gauss-Hermite approximation with p nodes can be
used. The Gauss-Hermite weight function is proportional to N(0, 2−1I) density, where I
is the identity matrix. Therefore a scaling transformation a(bi) = 2
− 1
2Bbi, where B is the
Cholesky factorisation of D, is used.
The Gauss-Hermite approximation to the likelihood of the random shared model with
right-censoring given by integral (85) is given by the weighted sum
L˜(Yi, Ti, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 φ(Yi(tij); Ŵi(tij), σ2e)[
f(Ti|21/2B−1Ei; θt, σ2)
]δi [S(Ti|21/2B−1Ei; θt, σ2)]1−δi φq(21/2B−1Ei;D),
(89)
where Ei are the abscissas, ω are the weights, p is the number of nodes, and
Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)(2
1
2B−1Eili) + U
T
i λ.
The Gauss-Hermite approximation to the likelihood of the random shared model with
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left-truncation and right-censoring given by integral (87) is given by the weighted sum
L˜(Yi, Ti, Ai, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 φ(Yi(tij); Ŵi(tij), σ2e)[
f(T ′i |21/2B−1Ei;θt,σ2)
f(Ai|21/2B−1Ei;θt,σ2)
]δi [ S(T ′i |21/2B−1Ei;θt,σ2)
S(Ai|21/2B−1Ei;θt,σ2)
]1−δi
φq(2
1/2B−1Ei;D),
(90)
where Ei are the abscissas, ω are the weights, p is the number of nodes, and
Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)(2
1
2B−1Eili) + U
T
i λ.
2.6.3 Laplace Approximation
Suppose there is an integral
∫
[exp l(t)] dt . The main goal is to approximate l(t) by a
Taylor series expansion about the maximum l(t)
l(t) ≈ l(tˆ) + ∂l(t)
T
∂t
|t=tˆ(t− tˆ) +
1
2
(t− tˆ)T l′′(tˆ)(t− tˆ), (91)
where l
′′
(tˆ) is the Hessian matrix evaluated at the maximum
l
′′
(tˆ) = ∂
2l(t)
∂t∂tT
|t=tˆ (50) (137).
At the maximum of l(t), the first derivative is zero. So, substituting l(t) by its Taylor
series expansion∫
exp[l(t)] dt ≈ ∫ exp[l(tˆ) + 1
2
(t− tˆ)T l′′(tˆ)(t− tˆ)] dt = exp[l(tˆ)] ∫ exp[1
2
(t− tˆ)T l′′(tˆ)(t− tˆ)] dt .
Thus, ∫
[exp l(t)] dt ≈ (2pi)Q2 det
{
−l′′(tˆ)
}− 1
2
exp[l(tˆ)], (92)
where Q is the dimension of t (50) (137).
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2.6.4 Laplace Approximation to Likelihood Integral
Suppose there is an integral
∫
[exph(bi)] dbi . The main goal is to approximate h(bi) by a
Taylor series expansion about the maximum h(bi):
h(bi) ≈ ˆh(bi) + ∂h(bi)
T
∂bi
|b=bˆ(bi − bˆ) +
1
2
(bi − bˆ)Th′′(bˆ)(bi − bˆ), (93)
((50),(137)), where h
′′
(bˆ) is the Hessian matrix evaluated at the maximum: h
′′
(bˆ) =
∂2h(bi)
∂bi∂bTi
|b=bˆ. At the maximum of h(bi), the first derivative is zero. So, substituting h(bi)
by its Taylor series expansion∫
exp[h(bi)] dbi ≈
∫
exp[h(bˆ) + 1
2
(bi − bˆ)Th′′(bˆ)(bi − bˆ)] dbi
= exp[h(bˆ)]
∫
exp[1
2
(bi − bˆ)Th′′(bˆ)(bi − bˆ)] dbi
= (2pi)
q
2 det
{
−h′′(bˆi)
}− 1
2
exp[h(bˆ)],
(94)
((50),(137)), where q is the dimension of b.
Laplace Approximation to likelihoods (83) and (86) is applied by using h(bi) = log bi to
change the form of the integrals.
The adjusted likelihood for (83) is
L(Yi, Ti, δi; θ) =
∫
exp [log [L(Yi|bi; (θy, σ2e))L(Ti, δi|bi; (θt, σ2))φq(bi;D)]]dbi, (95)
Applying Laplace approximation to (95), the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1 φ(Yi(tij); Ŵi(tij), σ
2
e)L(Ti, δi|bˆ; (θt, σ2))φq(bˆ;D), (96)
where Ωˆ = (−Hˆ)−1 is the asymptotic variance-covariance of Hˆ evaluated at mode bˆ.
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Similarly, the adjusted likelihood for (86) is
L(Yi, Ti, Ai, δi; θ) =
∫
exp [log [L(Yi|bi; (θy, σ2e))L(Ti, Ai, δi|bi; (θt, σ2))φq(bi;D)]]dbi, (97)
Applying Laplace approximation to (97), the approximate likelihood is
L˜(Yi, Ti, Ai, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1 φ(Yi(tij); Ŵi(tij), σ
2
e)L(Ti, Ai, δi|bˆ; (θt, σ2))φq(bˆ;D),
(98)
2.7 Applications to particular survival distributions
The main survival distributions that are used in practice are shown in Table 1 below.
Three of the survival distributions, Gompertz, Beard and Perks can be obtained from the
distributions in Table 1 by using transformations (see Appendices F, H and I for more
details).
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Table 1: Main Survival Distributions
Distributions Probability
Density Func-
tion
Cummulative
Distribution
Function
Survival
Function
Hazard
Function
Cummulative Haz-
ard Function
Weibull γn (
t
n )
γ−1e−(
t
n )
γ
1− e−( tn )γ e−( tn )γ γn ( tn )γ−1 ( tn )γ
Log-Logistic λpt
p−1
(1+λtp)2
λtp
1+λtp
1
1+λtp
λptp−1
1+λtp log[1 + λt
p]
Log-Normal e
− (log t−µ)
2
2σ2
tσ(2pi)
1
2
Φ[ log t−µσ ] 1−Φ[ log t−µσ ]
e
− (log t−µ)
2
2σ2
tσ(2pi)
1
2
1−Φ[ log t−µσ ]
− log(1−Φ[ log t−µσ ])
Extreme
Value
1
σ e
t−µ
σ −e
t−µ
σ 1− e−e
t−µ
σ e−e
t−µ
σ 1
σ e
t−µ
σ e
t−µ
σ
Logistic 1σ
e
t−µ
σ
[1+e
t−µ
σ ]2
e
t−µ
σ
1+e
t−µ
σ
1
1+e
t−µ
σ
1
σ
e
t−µ
σ
[1+e
t−µ
σ ]
log[1 + e
t−µ
σ ]
2.7.1 Shared parameter model with Weibull survival distribution
As an example of a parametric shared parameter model, the Weibull survival distribution
is considered. The longitudinal component is modelled with a linear mixed effects model.
The survival component is modelled using Weibull distribution. Theory required in joint
modelling distributions is provided in the Appendices (B)-(I).
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2.7.1.1 From Weibull distribution to model As can be seen from Table 1 the
survival function of Weibull distribution is given by
S(t;σ, γ) = exp
{−(tn−1)γ} , (99)
Write λ = n−γ, thus
S(t;λ, γ) = exp {−λtγ} . (100)
Take the log transformation of time (s = log t)
S(s;λ, γ) = exp {−λ exp {γs}} . (101)
Redefine parameters, γ = σ−1 and λ = exp {−µσ−1}, then the random variable s = log T
s = log T = µ+ σW, (102)
where W is the Extreme Value distribution with probability density function
fW (w) = σ
−1 exp {w − exp {w}} (103)
and survival function
SW (w) = exp {− exp {w}} . (104)
Substitute W = σ−1(s− µ) to obtain the probability density and the survival function of
log survival time. Therefore, the probability density function for s, for the ith individual
is:
f(si;µi, σ) = σ
−1 exp
{
σ−1(si − µi)− exp
{
σ−1(si − µi)
}}
(105)
and the survival function for the ith individual is:
S(si;µi, σ) = exp
{− exp{σ−1(si − µi)}} . (106)
2.7.1.2 Joint Modelling with Weibull survival sub-model The log survival time
for the ith individual, following Weibull distribution is given by
log Ti(ti) = µi(ti) + σ × i, (107)
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where i comes from Extreme Value distribution, σ is the scale and µi(ti) is given by
µi(ti) = αWi(t) +M
T
i γ, (108)
where γ is the regression coefficient that links the time-independent covariates, MTi , related
only to survival and Wi(t) is the longitudinal component.
The probability density and survival function of Weibull model are given by
f(Ti|bi; θ, t) = (t exp[µi(ti)])exp(1/σ−(t exp[µi(ti)])exp(1/σ)) (109)
and
S(Ti|bi; θ, t) = exp[−(t exp[µi(ti)])exp(1/σ)], (110)
respectively ((15),(63),(90)). For the longitudinal submodel, the probability density func-
tions of biomarker Yi(tij) conditional on random effects, and that of random effects bi are
given by
p(Yi|bi; θ) = (2piσ2e)−
1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1], (111)
and
p(bi; θ) = (2pi|D|)− 12 exp(−2−1b′iD−1bi), (112)
respectively, (139).
2.7.1.3 Joint Likelihood The Weibull joint likelihood contribution for right-censoring
only is
L(Yi, Ti, δi; θ) =
∏n
i=1 [
∫∞
−∞
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1b′iD−1bi)((ti exp[θx])exp(1/σ−(ti exp[µi(ti)])exp(1/σ)))δi
×(exp[−(ti exp[µi(ti)])exp(1/σ)])1−δi dbi ].
(113)
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Applying Gauss-Hermite approximation, the likelihood becomes
L˜(Yi, Ti, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 [(2piσ2e)− 12
× exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1/2B−1EiD−121/2B−1Ei)
×((ti exp[µi(ti)])exp(1/σ−(ti exp[µi(ti)])exp(1/σ)))δi
×(exp[−(ti exp[µi(ti)])exp(1/σ)])1−δi ,
(114)
where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)(2
1
2B−1Eili) + U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ.
Applying Laplace approximation the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1bˆ′iD−1bˆi)
×((ti exp[µi(ti)])exp(1/σ−(ti exp[µi(ti)])exp(1/σ)))δi
×(exp[−(ti exp[µi(ti)])exp(1/σ)])1−δi ,
(115)
where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)bˆ+ U
T
i λ and µˆi(t) = αWˆi(t) +M
T
i γ.
For the data with left-truncation and right-censoring, the likelihood is more complicated.
In this case,
L(Yi, Ti, Ai, δi; θ) =
∏n
i=1 [
∫∞
−∞
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1b′iD−1bi)
×( ((ti+Ai) exp[µi(ti)])exp(1/σ−((ti+Ai) exp[µi(ti)])
exp(1/σ))
(ti exp[µi(ti)])exp(1/σ−(ti exp[µi(ti)])
exp(1/σ))
)δi
×( exp[−((ti+Ai) exp[µi(ti)])exp(1/σ)]
exp[−(ti exp[µi(ti)])exp(1/σ)] )
1−δi dbi ].
(116)
When Gauss-Hermite approximation is applied, the likelihood becomes
L˜(Yi, Ti, Ai, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 [(2piσ2e)− 12
× exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1/2B−1EiD−121/2B−1Ei)
×( ((ti+Ai) exp[µi(ti)])exp(1/σ−((ti+Ai) exp[µi(ti)])
exp(1/σ))
(ti exp[µi(ti)])exp(1/σ−(ti exp[µi(ti)])
exp(1/σ))
)δi
×( exp[−((ti+Ai) exp[µi(ti)])exp(1/σ)]
exp[−(ti exp[µi(ti)])exp(1/σ)] )
1−δi ,
(117)
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where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)(2
1
2B−1Eili) + U
T
i λ and µˆi(t) = αWˆi(t) +M
T
i γ.
When Laplace approximation is applied, the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1bˆ′iD−1bˆi)
×( ((ti+Ai) exp[µi(ti)])exp(1/σ−((ti+Ai) exp[µi(ti)])
exp(1/σ))
(ti exp[µi(ti)])exp(1/σ−(ti exp[µi(ti)])
exp(1/σ))
)δi
×( exp[−((ti+Ai) exp[µi(ti)])exp(1/σ)]
exp[−(ti exp[µi(ti)])exp(1/σ)] )
1−δi ,
(118)
where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)bˆ+ U
T
i λ and µˆi(t) = αWˆi(t) +M
T
i γ.
2.8 Maximum Likelihood estimation of the parameters
The estimates of the parameters are obtained using maximum likelihood estimation. To
achieve this, the log-likelihood is differentiated with respect to each parameter, the deriva-
tive is set equal to zero and the resulting equations are solved in respect to each parameter
to obtain the maximum likelihood estimate θˆ, where θ = {θ1, ..., θK} is the set of all K
parameters, (63). The maximum likelihood equations are given by
∂l(θˆ; ti)
∂θk
= 0. (119)
In the above equation l(θ; t) denotes the log-likelihood, t is the set of time-points for
the ith individual, where i = 1, 2, ..., n and θk is the k
th parameter to be estimated, θ =
{θ1, θ2, ..., θK}.
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The Hessian matrix is given by
H[l(θ; y)] =

∂2l(θ;t)
∂θ21
∂2l(θ;t)
∂θ1 ∂θ2
· · · ∂2l(θ;t)
∂θ1 ∂θK
∂2l(θ;t)
∂θ2 ∂θ1
∂2l(θ;t)
∂θ22
· · · ∂2l(θ;t)
∂θ2 ∂θK
...
...
. . .
...
∂2l(θ;t)
∂θK ∂θ1
∂2l(θ;t)
∂θK ∂θ2
· · · ∂2l(θ;t)
∂θ2K

, (120)
(63). The information matrix is
I(θˆ) = −E[H[l(θ; y)]], (121)
(31) and the variance-covariance matrix is approximated by the inverse of the information
matrix ̂
V ar(θˆ) = I−1(θˆ), (122)
((8),(123)). The square roots of the diagonal elements of this matrix are the estimates
of the standard errors (SˆE(θˆ)) of each parameter, (63). The confidence intervals for the
estimates θˆ are obtained using θˆ ± z1−a/2SˆE(θˆ), where z1−a/2 is the upper a/2 percentile
of the normal distribution, (63).
2.9 Bootstrap estimation of the parameters
Bootstrap is an approach to statistical inference by resampling the data, (46). The idea
behind bootstrap is that the sample is to bootstrap samples what the population is to
sample, (46). There are different forms of bootstrap, but here the nonparametric bootstrap
is used, because it allows to estimate the sampling distribution empirically without making
assumptions about the population, (46).
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The algorithm for non-parametric resampling is as follows, (19):
1. Sample s observations randomly, with replacement, to create a bootstrap set Y ∗b out
of the original sample yobs.
2. Calculate the bootstrap version of the statistics ψ∗b = ψ(Y
∗
b )
3. Repeat the first two steps B times to obtain a boostrap estimate.
The estimates can be obtained by using
ψ̂∗ =
B∑
b=1
ψ̂∗(b)
B
(123)
((34),(36)) and their standard errors are
sˆeB =
√√√√ 1
B − 1
B∑
b=1
[ψˆ∗(b)− ψˆ∗]2, (124)
((34),(36)).
These are used to estimate the parameters, the standard errors of the parameters and then
the confidence intervals.
For bootstrap confidence intervals, there exist many different methods (46). This the-
sis is using the percentile method, which uses the empirical quantiles of ψˆ∗(b) to form
the confidence interval and does not requite the evaluation of standard errors (46). Let
ψˆ∗(1)(b), ψˆ
∗
(2)(b), ..., ψˆ
∗
(B)(b) be the ordered bootstrap estimates, the lower limit of the confi-
dence interval is ψˆ∗[(B+1)a/2] and the upper limit is ψˆ
∗
[(B+1)(1−a/2)]. (46).
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2.10 Summary
This chapter described a shared parameter model for longitudinal and survival data under
left-truncation and right-censoring. A linear mixed effects model was described to model
the longitudinal component and a general class of parametric survival models to model the
survival component. Two approximations were explored for the likelihood integral of the
model. The two methods, maximum likelihood and bootstrap are described for the estima-
tion of the parameters. Even though both Gauss-Hermite and Laplace approximations are
described, only Gauss-Hermite approximation is used in my R program which implements
joint modelling.
The next chapter describes the simulations for the joint model with a Weibull survival sub-
model, as presented in this chapter and the R program written to implement this method
and used for simulations.
53
3 Simulation Study
3.1 Introduction
In the previous section, a shared parameter model for longitudinal and time-to-event data,
under left-truncation and right-censoring was introduced. As stated in the previous chap-
ter, Gauss-Hermite approximation was applied to obtain the parameters.
In this chapter, the estimation quality for the proposed ML and the bootstrap methods
for a Weibull survival sub-model is assessed. Estimates of the mean and the median bias
of the estimators, the standard errors, and the actual coverage at 95% nominal level are
calculated. The results from the lme (100), package for the longitudinal component, and
from the survreg (130) and aftreg (15) survival packages for the survival component are
compared with those from the joint model, and the results from jointModel (110) are also
compared to assess the model fit in comparison with other joint models. For survreg only
the first observation on the time-dependent covariate was used as it cannot handle time-
dependent covariates. On the contrary, aftreg can handle time-dependent covariates, but
it cannot handle random effects. lme can only handle longitudinal data and not survival
data. R documentation is provided for the programs that were created to fit the models
and to simulate the data in the Appendix J.
3.2 Design
The joint model framework is a rather complex framework and thus, the simulations needed
to be quite simple for the computers to handle. This was mainly the criterion for the
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simulations described below.
The simulations are based on the Weibull survival sub-model for n = 100 and n = 500
patients, using 500 replications for each scenario. Ten Gauss-Hermite points were used for
ML estimation, and 100 bootstrap samples for bootstrap-based estimation.
The left-truncation time ti0 is taken to be zero, and the first observation for each patient
was made at 0. The subsequent observation times for each patient were generated from
the Poisson process with intensity 3 or 23, right-censored at 1. This resulted in 1 to 4 and
1 to 24 observations per patient, respectively.
For simplicity, time-dependent covariate XTi (tij) = tij and for each time-point tij, the
biomarker values Yi(tij) are simulated as
Yi(tij) = tijβ + bi + λ+ eij, (125)
where the univariate random effects bi are generated from N (0, D) and the errors ei(tij)
are independently generated from N (0, σ2e). The variances were chosen as D = 0.1 and
σ2e = (0.1)
2.
For survival, the time-independent covariates MTi include an intercept (taken to be zero)
and a binary (0 or 1) factor gi such as gender, with the values generated from the Bernoulli
distribution with the probability of success 0.5.
Leemis et al.(1989) denote the cummulative link function as Ψ(t) = ψ(F (T ); η), where
F (T ) is the covariate history and η is the set of covariate parameters, and generate survival
time T using the algorithm Ψ−1(H−10 (−log(1 − u))), for u ∼ Unif(0, 1). H−10 (t) is the
inverse cummulative baseline hazard function of H0(t) = (tσ
−1)γ. The model here is
log(T ) = α(tijβ + bi + λ) + γ1 + γ2M
T
i + σ, where  comes from the Extreme Value
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distribution and thus the baseline distribution is Weibull.
So, Ψ(T ) =
∫ T
0
exp[α(tijβ + bi + λ) + γ1 + γ2M
T
i + σ]dt
= (αβ)−1 exp[αβ](exp[α(Tβ + bi + λ) + γ1 + γ2MTi + σ]− 1).
The inverse function is Ψ−1(z) = (αβ)−1 log[1 + exp[−(α(λ+ bi) + γ1 + γ2MTi )]βαz].
The baseline hazard for Weibull distribution is H0(t) = (tσ
−1)γ and the inverse function is
H−10 (z) = σz
γ.
Generating Weibull survival time T = Ψ−1[H−1(− log(1− u))] = Ψ−1[σ(− log (1− u))γ]
Thus, the time T ∗ is simulated as
T ∗ = (αβ)−1 log(1 + exp(−(α(λ+ bi) + γ1 + γ2MTi ))αβσ(− log(1− u))γ, (126)
where u ∼ Unif(0, 1).
We aimed at no more than 20% of the total data to be censored. First, we have used
Bernoulli random number generator with probability of success 0.2 to select censored pa-
tients. For censored patients, the censoring times Ci are simulated from the uniform
distribution (0, T ∗i ). Otherwise Ci =∞.
The observed survival time is Ti = min(T
∗
i , Ci).
Scenario 1 has only the longitudinal component i.e. α = 1, β = 1, λ = 1, γ1 = 0, γ2 = 0.
Scenario 2 includes both longitudinal and survival parts, with the parameters α = 1, β = 1,
λ = 1, γ1 = 0, γ2 = 1. These scenarios were chosen because the joint model needed to be
assessed when one of its two parts (longitudinal or survival) was zero and when both of
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them were not zero.
Simulations were comparatively slow and needed large memory. The time needed for the
task to complete was increasing exponentially with the number of patients and the number
of observations. Personal computers could not handle the simulations. Therefore, they
were run on a high performance compute cluster (HPC) that is available at University
of East Anglia. Many dedicated nodes were assigned for this task because of previous
attempts failing on shared nodes. Even then, the scenario with 500 patients and up to 24
observations, took more than two months to complete. The scenario for 100 patients with
up to 4 observations, took around 2 weeks.
3.3 Results
Results of our simulations are presented in Tables 2 to 9.
For survreg, most of the estimates are considerably biased. This is as expected because
it cannot handle time-dependent covariates. However, it estimates the survival slope γ2
in scenarios 1 quite accurately, and provides fair coverage for it. It is not clear why it
performs much worse in scenario 1. It does not estimate the survival error variance log(σ)
well in any of the scenarios.
For aftreg, survival slope γ2 is estimated accurately in scenario 1, with a reasonable cover-
age. The rest of the estimates are biased in all scenarios. This is probably due to the fact
that aftreg cannot handle random effects.
For lme, the point estimation of all longitudinal parameters is very accurate, including the
variance components, but the coverage of β seems to drop when the number of patients
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increases.
In the joint modelling, the analytical point estimators for all regression parameters are quite
accurate in both scenarios with the exception of γ1, β when the the number of patients is
500 and the number of observations=23 for both scenarios, α when the number of patients
is 100 and the variance of the random effects. In bootstrap, all estimates are not good
with the variances being the exception.
All analytical coverage is bad, with the exception of the coverages for survival intercept γ1,
survival slope γ2 and shared parameter α. Coverage, however, from analytical estimates
and bootstrap errors always includes the actual value. Using analytical point estimators
with bootstrap standard errors results in reliable though mostly too conservative coverage
for all parameters.
Coming to the estimation of the association parameter α, there is a clear difference between
analytical and bootstrap estimation. Analytical estimation results in a really small bias for
both scenarios when the number of patients is relatively small, while bootstrap estimation
is always biased for both scenarios. To summarise, it appears that the safest option is to
use analytic estimation with bootstrap standard errors.
JM provides unbiased estimates for both scenarios with really good coverage. The only
exception is the survival intercept γ1 which is biased in all scenarios, but still has a good
coverage when the number of patients is 100 and a fair coverage when the number of
patients is 500.
It is fair to say that JM program is indeed the ’gold standard’ of joint modelling and
definitely better from our program.
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3.4 Summary
In the previous chapter, a shared parameter model for longitudinal and time-to-event data,
under left-truncation and right-censoring was introduced. Gauss-Hermite approximation
was applied for maximum likelihood estimation. This chapter described the simulation
scenarios and the estimation quality of the parameters for the model described in the
previous chapter, using a Weibull survival sub-model.
The estimation quality for the proposed maximum-likelihood and the bootstrap method
were assessed in respect to the mean bias of the estimators, the standard errors, and the
actual coverage at 95% nominal level for a Weibull survival sub-model. Median was not
used as it provided no different results than the mean. Results were compared to the
results from the lme package for the longitudinal component, and to the results from the
survreg, aftreg survival packages for the survival component and the joint modelling JM
package.
The program implementing this method and providing two estimation procedures (an-
alytical and bootstrap) was assessed by simulation using 10 nodes for Weibull survival
distribution.
Overrall, the analytical procedure is quite good, though the variance components are not
estimated with sufficient quality. This could be due to a fair number of nodes, but it should
be noted that the increase in number of nodes increased the computing time exponentially.
The most trustworthy method is to combine the analytic point estimation with bootstrap
standard errors. Rizopoulos program, however, is more reliable in providing more accurate
estimates.
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The details enabling the application of the joint modelling theory to other parametric
distributions can be found in the Appendices C-I. However, it should be noted that the
quality of our procedure for other parametric models needs to be assessed by simulation.
The next chapter will provide two medical applications of the shared parameter model
with Weibull survival distribution.
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4 Applications
4.1 Introduction
In the previous chapter, the estimation quality for the proposed maximum-likelihood and
the bootstrap methods in respect to the mean bias of the estimators, the standard errors,
and the actual coverage at 95% nominal level for a Weibull survival sub-model were assessed
and compared with the results from the lme package for the longitudinal component, and
from the survreg and aftreg survival packages for the survival component.
In this chapter the shared parameter model with the Weibull survival submodel presented
in this thesis will be used to analyse two medical datasets, the Prostate Cancer data and
Primary Biliary Cirrhosis data.
4.2 Prostate Cancer Data
4.2.1 Introduction
Prostate cancer (PCa) is the growth of cancerous cells in the prostate (26). The easiest
clinical way to diagnose it is through PSA (Prostate-Specific Antigen) screening.
The human-specific prostate antigens were identified in 1960, but they could not be isolated
(44). Later on, investigations on human semen led to the discovery of a unique antigen,
similar to PSA (53) (54) and in 1980 it was found that PSA in prostate was similar to the
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PSA in serum. From that point prostate cancer could be diagnosed by a serum test (96).
Thus, PSA can be used as a longitudinal biomarker for prostate cancer and therefore it
can be used as an example for the joint modelling methodology that is developed in this
thesis. PSA can be used as a diagnostic biomarker for prostate cancer screening, and also
as a prognostic biomarker, to ascertain the possible course of cancer and its treatment.
Prostate cancer screening has been controversial, however, and randomized trials gave
conflicting results. Schroder et al (2009) (117) and Welch and Albertsen (2009) (147)
found that PSA screening leads to overdiagnosis, but Schroder et al (2009) (117) also
found that PSA screening decreased the death rate, while Andriole et al (2009) (7) and
Sandblom et al (2011) found that for both male groups in their study, the screening group
and the control group, the rate of death from prostate cancer did not differ significantly.
PSA value boundary for prostate cancer is even more controversial. Some researchers found
that no PSA value boundary can be set and that new biomarkers need to be associated
with prostate cancer (57) (61), while others concluded that limit values for PSA can be
set, but only when there are no additional risk factors (116). In the presence of other risk
factors, the PSA values cannot be considered as accurate diagnostic tools (116). Other
researchers provide more specific PSA limits for different ages. Vickers et al. (140) found
that 60-year-old males that have PSA less than 1 nm/ml might develop a prostate cancer,
but it will not possibly be fatal and thus, no further screenings are required. Other authors
categorized the PSA values into 3 different categories for males at the age of 60 (18). They
concluded that males that have a PSA level more than 2 ng/mL, should undergo further
screening, while those with PSA level less than 1 ng/mL do not need to do this. For PSA
levels of 1-2 ng/mL it is not clear what the best strategy is (18).
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4.2.2 Data Description
The data on PCa were provided by Bettencourt-Silva et al.(2011) (11). These data were
collected from multiple hospital information systems in Norfolk and Norwich University
Hospitals (administration, biochemistry, histopathology, radiotherapy, radiology, oncology)
and were validated and complemented with data from the local cancer registry. Further
information on data collection methods can be found in Bettencourt-Silva et al.(2011) (11).
The data collection covered the period from 6/1/2004 to 26/7/2014. The entry age is up
to 75 years (inclusive). The initial number of patients was 1154. 7 patients that had had
other cancers, before they were treated for prostate cancer were removed from the data,
resulting in the total sample size of 1147.
We have grouped the treatments into the following four types on the intention to treat
basis: Hormone therapy (H), Hormone and Radiotherapy (HR), Surgery (S) or Watchful
Waiting (W).
A list of pre-existing comorbidities was compiled from hospital records. These were subdi-
vided into the following three classes: Heart (CVA/CVD-Ischaemic heart and Cerebrovas-
cular diseases), Respiratory (Chronic Lower Respiratory diseases and Infuenza and Pneu-
monia), and Prostate diseases (Inflammatory disease of Prostate, Prostate hyperplasia and
other disorders of the Prostate). For more details see Table 11.
A comprehensive list of blood test results up to one year prior to prostate cancer treatment
was compiled by Bettencourt-Silva et al.(2011) (11). The blood test results used in further
survival modelling included: urea, white blood count (WBC), creatinine, haemoglobin
(Hg), Mean Corpuscular Volume (MCV), Mean Corpuscular Haemoglobin (MCH) and
67
Sodium. See Table 12 for details.
Multivariate survival modelling included patients at cancer stage 2 with treatments H, HR,
S and W; cancer stage 3 with treatments H, HR and S, and cancer stage 4 with treatment
H. There were not enough patients and/or events for other stage/treatment combinations.
For instance, there were only 9 deaths in 124 patients at cancer stage 1. We also excluded
26 patients at cancer stage 4, 34 patients at stage 2 and 34 patients at stage 3 who received
‘atypical’ treatments. These 218 patients in total were excluded from survival modelling.
The final dataset also includes cancer staging (2 to 4) which shows how far the cancer has
spread. For patients with cancer stage 2 (Total: 662) there are 87 patients that take H
treatment, 212 that take HR treatment, 272 that take S treatment and 91 that take W. For
the patients that have cancer stage 3 (Total: 206), 31 receive H treatment, 39 are under
HR treatment and 136 took S treatment. The 67 patients that have cancer stage 4 are
under H treatment. See Table 10 for more details.
Table 10 also includes information on PSA measurements (these are right-skewed, and
some are missing), and death (165 patients out of the 935 patients died i.e. 17.65%).
Most of the 935 remaining patients (91.97% of the patients) are also ascribed a Gleason
score. This is based on a biopsy and it shows how aggresive the cancer is, i.e. how likely
the tumour it is to grow and spread outside the prostate (67). For a patient, Primary
and Secondary Gleason scores are recorded, but the medical professionals often use sum
Gleason, i.e. if the Primary and the Secondary Gleason are 3, then the sum Gleason would
be 6. Sum Gleason is divided into two categories, where the sum is ”6 or 7” for 701 patients
(74.97%), or ”8 to 10” for 159 patients (17.01%). See Table 13 for more details.
PSA measurements are right-skewed with minimal missing percentage (Check Table 10).
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4.2.3 Methods for standard Survival Analysis of Prostate Cancer Data
In this and the next section we consider the values of predictors recorded up to a year
before treatment. The reason behind that is because treatment may affect some of the
blood value like PSA and because not all patients had blood measurements right before
treatment.
Kaplan-Meier survival curves were used to estimate survival by treatment and by stage.
Cox proportional hazards regression was used to model the survival time of the cancer
patients. Survival package (130) in R statistical software (103) was used for analysis.
We have considered the following list of possible predictors of survival: age at diagnosis,
stage and Gleason score, treatment type on the intention to treat basis, pre-existing co-
morbidities by class, PSA and various blood test results (see above). All these predictors
were initially included in the model.
Backward elimination at 0.1 significance level was used to obtain the final model.
Proportional hazards assumption was tested by using a chi-square test of 4 different survival
time transformations (identity, log, Kaplan-Meier and rank) with the scaled Schoenfeld
residuals. The quality of the model was assessed by using the Akaike Information Criterion,
Cook’s distance (63), O’ Quigleys R2 (70) and Concordance (49). The values of these
parameters for the final model are AIC=994.61, 0% of the data has Cook’s distance larger
than 1, O’ Quigleys R2 = 0.63and Concordance = 0.75.
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Figure 1: Kaplan-Meier Plot for Prostate Cancer Survival by Cancer Stage and Treatment
74
Figure 2: Kaplan-Meier Plot for Prostate Cancer Survival by Sum Gleason Scores
75
Figure 3: Kaplan-Meier Plot for Prostate Cancer Survival by PSA
Figure 1 shows the Kaplan-Meier Plot for Prostate Cancer Survival by Cancer Stage and
Treatment. All groups include censored and dead people by the end of the study. Not all
curves, however, drop to zero. When the survival curve drops to zero, it does not mean that
all patients in the study died. The curve drops to zero when there is a death after the last
censoring and it remains higher when there is no death after the last censoring. So, W2, S2,
H3 and H4 groups drop to zero because there were deaths within remaining patients, after
the last censoring. H2, HR2, HR3, S3 do not drop to zero because after the last censoring
there were no deaths and there are still people alive that haven’t being censored or died,
making the probability of surviving higher than zero. It should be noted that when there
are censored patients, the bottom point of the Kaplan-Meier survival curve is not equal to
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the fraction of the patients that have survived. A patient, contributes to this fraction up
until he is censored. After censoring the patient does not affect the calculations.
4.2.4 Results of the standard Survival Analysis of the Prostate Cancer Data
Kaplan-Meier plots for Prostate Cancer are given in Figures 1-3. They show that Hor-
mone treatment at all stages seems to have the lowest survival compared with the other
treatments, Gleason level 8 to 10 results in worse survival than 6 or 7 and this is also true
for PSA larger or equal to 10 compared to PSA less than 10.
In the Cox modelling, the continuous PSA was found not to be significant and we used
PSA categorised into two categories in further analysis.
The final Cox regression for survival of the prostate cancer patients is given below. The
model includes age at diagnosis, Gleason score category, treatment and stage, PSA cat-
egory, urea and WBC. The model is based on 666 patients with 96 events. 269 patients
were excluded due to missing values in some of the predictors.
Comparing Hormonal treatment across stages we can see the deleterious effect of a higher
cancer stage. Survival with hormonal treatment does not differ between stages 2 and 3,
but both are significantly better than survival at stage 4 (the baseline), with hazard ratios
of survival 2.11 and 2.15, respectively. Hormonal treatment results in the worst survival at
all stages, and we shall treat this treatment as the baseline for further comparisons within
each stage. At stage 2, Surgery provides 1.320 times better hazard of survival, the HR
therapy provides 2.381 times better hazard of survival. The Watchful Waiting provides
1.161 times better hazard of survival. At stage 3, Surgery provides 2.400 times better
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hazard of survival and HR provides 1.257 times better hazard of survival. Higher age of
diagnosis results in worse survival, the hazard of death increasing 1.04 times per year of
age. Combined Gleason score above 7 results in 2.5 times higher hazard of death. The
PSA of 10 or above prior to diagnosis results in 1.74 times higher hazard of death. Urea
and WBC count are also significant, resulting in 43.380 and 6.890 times higher hazards
per unit, respectively.
Table 14: Cox Proportional Hazards Model for PCa
estimates coef se(coef) p
age 0.039 0.023 0.085
treatment and stage H2 -0.746 0.375 0.046
treatment and stage H3 -0.764 0.479 0.111
treatment and stage HR2 -1.614 0.411 0.000
treatment and stage HR3 -0.992 0.492 0.044
treatment and stage S2 -1.024 0.410 0.012
treatment and stage S3 -1.639 0.531 0.002
treatment and stage W2 -0.896 0.538 0.096
PSA 10andmore 0.554 0.262 0.035
gleason 8to10 0.915 0.255 0.000
log(Urea) 1.328 0.392 0.001
log(White Blood Count) 0.655 0.392 0.095
4.2.5 Time-dependent and Joint modelling of Prostate Cancer Data
On average there were 23 longitudinal observations of PSA per patient (Total: 839 pa-
tients).
Initially a survival model with time-dependent covariates was fitted using aftreg program
from eha R package (15). When a main-effects model (see below) was fitted the results
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were similar with standard survival analysis. But PSA as factor was not signifficant and
PSA continuous had a coefficient of −0.001 (see Table 15). The program failed to estimate
numerous standard errors and therefore, the p-values were not available (for PSA inclusive).
Blood tests and comorbidities were not signifficant.
Table 15: Time-Dependent Main-Effects aftreg Model for PCa
Covariate Coef se(Coef) p
age -0.074 NaN NaN
gleason -0.799 0.089 0.000
treatment and stage H2 0 (reference)
treatment and stage H3 -0.122 0.252 0.628
treatment and stage H4 -0.344 0.229 0.133
treatment and stage HR2 0.276 0.200 0.168
treatment and stage HR3 0.020 0.238 0.933
treatment and stage S2 0.249 0.241 0.301
treatment and stage S3 0.231 0.281 0.411
treatment and stage W2 0.061 0.268 0.821
PSA -0.001 NaN NaN
log(scale) 13.854 NaN NaN
log(shape) 0.359 NaN NaN
When an interaction of PSA with stage and treatment and sum of Gleason scores was
introduced, the results made no sense even though all terms were signifficant (see Table
16). One of the problems is that the higher the PSA was, the higher the log survival
time was. To understand this in terms of the interactions, let two patients have a PSA
value 5 and 10, with treatment and cancer stage S3 and sum Gleason scores 8 to 10
being the same. For the patient with PSA= 5, the log(survival time)= 5 × (−0.012 +
0.011+0.247)+0.159−0.603 = 0.786, while for the patient with PSA= 10 the log(survival
time)= 10 × (−0.012 + 0.011 + 0.247) + 0.159 − 0.603 = 2.016. This shows that the
patient with higher PSA has a higher log(survival time), which contradicts established
view. Another problem is that surgery in stage 2, S2 seems to have the worse log(survival
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time) than W2, when in the Cox proportional hazards model it was the other way around.
Table 16: Model with Time-Dependent Covariates with interactions for PCa obtained by
aftreg
Covariate Coef se(Coef) p
age -0.054 0.013 0.000
gleason -0.603 0.140 0.000
treatment and stage H2 0 (reference)
treatment and stage H3 -0.090 0.232 0.698
treatment and stage H4 -0.301 0.214 0.161
treatment and stage HR2 0.265 0.184 0.150
treatment and stage HR3 0.058 0.230 0.801
treatment and stage S2 0.192 0.212 0.365
treatment and stage S3 0.159 0.283 0.574
treatment and stage W2 -0.024 0.432 0.956
PSA -0.012 0.001 0.000
gleason : PSA 0.011 0.001 0.000
treatment and stage H3: PSA -0.001 0.000 0.000
treatment and stage H4: PSA 0.001 0.000 0.000
treatment and stage HR2: PSA -0.012 0.002 0.000
treatment and stage HR3: PSA -0.001 0.001 0.029
treatment and stage S2: PSA -0.001 0.000 0.000
treatment and stage S3: PSA 0.247 0.353 0.485
treatment and stage W2: PSA 0.045 0.053 0.391
log(scale) 12.413 0.970 0.000
log(shape) 0.578 NaN NaN
The analyses using the JM package (with a Cox proportional hazards sub-model and a
Weibull sub-model in accelerated failure time form), have not converged. The joint model
presented in Chapter 3 also gave odd results. The model found a positive relation between
log(PSA) and log(survival time), i.e. increase of log(PSA) by 1, increases log(survival time)
by 0.217, see Table 17. There were also an attempt to fit the ratio of the PSA value at each
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time point over the first PSA measurement and different PSA transformations, but this
led nowhere. A possible reason for the peculiar results of the time-dependent analysis and
joint analysis is that PSA is not a good biomarker and indicator of the Prostate Cancer.
Table 17: Analytical Joint Model for PCa
analytical estimates parameters se p
sigma.e 0.921 NA NA
alpha 0.217 NA NA
log.sigma 0.844 NA NA
time 0.000 NA NA
longitudinal intercept 3.932 NA NA
gleason -0.439 NA NA
treatment and stage H2 -0.512 NA NA
treatment and stage H3 -0.061 NA NA
treatment and stage HR2 -0.131 NA NA
treatment and stage HR3 1.005 NA NA
treatment and stage S2 -0.300 NA NA
treatment and stage S3 -0.079 NA NA
treatment and stage W2 -0.063 NA NA
survival intercept -0.414 NA NA
D11 0.283 NA NA
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Table 18: Bootstrap Joint Model for PCa
bootstrap estimates parameters se p
sigma.e 0.918 0.001 0.000
alpha 0.090 0.022 0.000
log.sigma 0.842 0.003 0.000
time 0.001 0.000 0.000
longitudinal intercept 3.864 0.019 0.000
gleason -0.554 0.019 0.000
treatment and stage H2 -0.507 0.012 0.000
treatment and stage H3 -0.027 0.022 0.220
treatment and stage HR2 -0.159 0.029 0.000
treatment and stage HR3 1.137 0.020 0.000
treatment and stage S2 -0.107 0.031 0.001
treatment and stage S3 0.030 0.023 0.178
treatment and stage W2 0.160 0.020 0.000
survival intercept -0.176 0.020 0.000
D11 0.281 0.001 0.000
4.3 Primary biliary cirrhosis (PBC2) data
4.3.1 Data Explanation
Primary Biliary Cirrhosis (PBC) is an autoimmune disease of the liver, see (58) for more
details. The Mayo Clinic conducted a follow-up study of 312 patients with the diagnosis of
PBC from 1974 to 1984, (91) to compare a drug D-penicillamine (158 patients) to placebo
(154 patients). The PBC dataset used here was taken from the JM package, (110). It
contains 1945 total observations, i.e. 6.23 observations per patient on average over time,
spanning from year 1 to year 11. The median follow-up time was 6.3 years. At each patient
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visit the serum bilirubin (a biomarker) measurement (in mg/dl) was taken. Higher values
of serum bilirubin are considered to be a strong indicator for the disease progression.
Instead of working with serum bilirubin, we are using its log transformation due to its
right-skewneness. The patient’s age in years at registration (26 to 78 years) is considered
to be the truncation time for our model with left-truncation and right-censoring. Time of
each visit is counted from registration. The right censoring is due to liver transplantation
or the end of the study. By the end of the study 140 patients were dead (69 and 71 in
placebo and treatment arms, respectively), and 172 were censored out. See Tables 19 and
20 for more details.
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4.3.2 Methods
A Weibull-based analytical model with bootstrap errors for the case of left-truncation and
right-censoring was fitted to the data. In this model, the log survival time is given by
log Ti = α[βt+ bi + λ] + γ1 +M ∗ γ2 + σ × i. (127)
In the above model, the biomarker Y (t) (log serum bilirubin) depends on the time of
its measurement t (a time-dependent covariate), the patient id (as a random effect bi)
and includes an intercept λ. The survival submodel additionally includes the binary factor
treatment denoted by M and taking on values 0 and 1, and an intercept γ1. The association
of log(serum bilirubin) with log(survival time) is denoted by α, and log σ is the scale.
We are mainly interested in the effect that serum bilirubin has on survival time and the
changes in serum bilirubin over time, i.e. the association α of the longitudinal biomarker
with the log survival time and β.
4.3.3 Results
The coefficients of the fitted model are given in Table 21. The results show that log(survival
time) is associated with log(serum bilirubin) negatively, with the slope of α = −0.386.
Every additional year of the PBC progression decreases the survival time exp(0.386 ×
3.934) = 4.57 times on average. When the patient is on D-penicillamine, the survival time
increases exp(0.51) = 1.67 times, compared to being on placebo.
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Table 21: PBC Left-Truncated and Right-Censored Model
estimates parameters se p lower upper
sigma.e 0.555
alpha -0.386 0.021 0.000 -0.428 -0.344
log.sigma 0.685 0.003 0.000 0.679 0.691
year(β) 3.934 0.023 0.000 3.888 3.979
intercept within longitudinal(λ) -0.265 0.016 0.000 -0.297 -0.233
intercept within survival(γ1) -0.319 0.013 0.000 -0.346 -0.293
drug(γ2) 0.510 0.012 0.000 0.488 0.533
D11 0.103
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4.3.4 Regression Diagnostics
There are no known regression diagnostics methods for parametric joint modelling. Even
though this research was not about the regression diagnostics of this type of models, there is
a need for developing such tools, and it will be explored in the future. A first thought and a
preliminary work on this is to plot scaled score residuals, Cook’s distance versus Martingale
residuals and cummulative Kaplan-Meier versus Cox-Snell residuals. These were explained
in Chapter 2 and they are used for assessing the fit of a parametric survival model, but a
further investigation needs to be done for their use in parametric joint modelling.
For a plot of a cummulative Kaplan-Meier versus Cox-Snell residuals the closer the step
function is to the line passing from point (0, 0) with gradient 1, the better the fit is. In
the PBC example, the joint model seems to be fitting the data really well, except perhaps
near (0, 0). See Figure 4. Figure 5 should provide an indication of poorly fitted influential
observations. There are 7 patients that have larger absolute martingale values than the
rest, but these values are not too large to conclude that they are poorly fitted. Overall,
the Cook’s distance seems to be well under 1, which indicates that no patient affects the
estimates more than the other patients. In Figures 6 to 10, the scaled score residuals seem
quite dispersed, but in fact they are not too far away from each other taking into account
the scale of the graphs.
Overall, based on these 3 diagnostic methods the model seems to fit well to the data.
However, it should be noted that, to the author’s knowledge, there is no research indicating
how well these 3 methods can perform for a parametric joint model. This is an area for a
future research.
It should be noted that there were not any diagnostics for the joint model for PCa, because
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it made no sense.
Figure 4: Cummulative Kaplan-Meier Vs Cox-Snell Residuals
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Figure 5: Cooks Distance Vs Martingale Residuals
Figure 6: Scaled Score Residuals for association
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Figure 7: Scaled Score Residuals for drug
Figure 8: Scaled Score Residuals for log(sigma)
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Figure 9: Scaled Score Residuals for longitudinal intercept
Figure 10: Scaled Score Residuals for survival intercept
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4.4 Summary
In this chapter the shared parameter model with Weibull survival sub-model presented in
Chapter 3, was applied to two datasets. For prostate cancer data, the joint model did
not work well possibly due to the fact that PSA is not a reliable biomarker. For the
primary biliary cirrhosis data, the joint model provided reasonable results explaining the
data well. The regression diagnostics also indicated that the model fits well to the data,
but further investigation needs to be done for the use of diagnostic methods on parametric
joint modelling.
In the next chapter the future extensions of the joint model are presented.
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5 Future Developments
The simple version of longitudinal data for joint modellling is to have one longitudinal
biomarker. There are however, more complicated scenarios where there are multiple longi-
tudinal biomarkers. Additionally, there may be different types of failing. Models that can
handle different types of failing are called competing risks models. These different types
of failing can also be considered as informative censoring.
Rizopoulos and Ghosh (2011) (114) suggested a joint model relating multiple longitudinal
biomarkers to time-to-event data. They assumed that the baseline risk function is piecewise
constant and they used a spline-based method for longitudinal outcomes.
Albert and Shih (2011) (5) extended the two-stage regression calibration approach, used in
Albert and Shih (2010), for multiple longitudinal measurements and discrete time-to-event
data. First, they fitted a longitudinal model for multiple longitudinal measurements and
then this model was related to the survival model, while informative drop-out was dealt
by regression calibration. They used a two-staged procedure. At first, they fit multivariate
linear mixed models to the longitudinal data and then they estimate the time-to-event
model by replacing the random effects with corresponding Bayes estimates. For standard
errors the bootstrap procedure is used.
Elashoff, Li and Li (2007) (38) extended the work of Henderson et al (2000) (56). They
suggested a joint model for repeated measurements and competing risks failure time data,
which considers more than one failure types. The longitudinal components and the com-
peting risks failure time data are linked together by latent random variables. They assume
that each subject can experience one of g distinct failure types or can be right-censored.
Their joint model consists of a linear mixed effects model for the longitudinal component, a
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marginal probability of the ith subject failing from kth risk and a conditional cause-specific
hazard model for the kth risk.
In this chapter future extensions of the shared parameter model presented in chapter 3 are
presented. These are a shared parameter model with multiple biomarkers and competing
risks, under left-truncation and right-censoring.
5.1 Joint Modelling with Multiple Longitudinal Markers
5.1.1 Longitudinal Sub-Model
Suppose there are n individuals which we observe at mi time points each. These could
be different for each individual. Let β be a vector denoting time-dependent fixed effects
and bi be a vector denoting the random effects for the i
th individual, where i = 1, 2, ..., n.
Let λ be a vector denoting the time-independent fixed effects. Suppose Yik(tijk) is the
observed value of the kth longitudinal biomarker for the ith individual at the jth time point,
where j = 1, 2, ...,mi, k = 1, 2, ..., K. All biomarkers may not have the same timepoints.
Wik(tijk) is the conditional expectation of the k
th longitudinal biomarker Yik(tijk) for the
ith individual at the jth time-point, given bik. bi = bi1, ..., biK are the random effects for the
ith individual for the kth biomarker.
The observed values of the longitudinal biomarkers are
Yik(tijk) = X
T
ik(tijk)β + Z
T
ik(tijk)bik + U
T
ikλ+ eik(tijk). (128)
Let Yik = {Yi1, Yi2, ..., YiK} be the set of the kth longitudinal biomarkers for the ith in-
dividual that includes all time points, to make notation easier. eik(tijk) is a mik × 1
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vector that denotes measurements errors. eik(tijk) is independent of all variables and
has independent marginal distribution N(0, σ2e). The correlation between repeated mea-
surements, for the same kth longitudinal biomarker, in longitudinal process is given by
cov(ei(tijk), ei(tij′k)) = 0 for j 6= j′. For each kth longitudinal biomarker, suppose, there
exist r time-independent fixed parameters and thus, λ is a r×1 vector of time-independent
fixed effects that links UTi , a mi×r matrix to the longitudinal observations Yi(tij). If there
are q random effects, then bi is a q × 1 vector, while ZTi (tij) is a mi × q design matrix for
random effects. bi ∼ MVN(0, D) and D is a q × q variance-covariance matrix. Assuming
that there are p time-dependent fixed parameters, β is p× 1 vector and XTi (tij) is a mi× p
design matrix for time-dependent fixed effects.
Now, let
Wik(tijk) = X
T
ik(tijk)β + Z
T
ik(tijk)bik + U
T
ikλ. (129)
Thus, the model is given by
Yik(tijk) = Wik(tijk) + eik(tijk). (130)
5.1.2 Survival Sub-Model
Let T ∗i denote the true survival time for the i
th individual. Let Ci and Ai denote the
censoring and truncation time for the ith individual. The observed survival time for the ith
individual is given by Ti = min(T
∗
i , Ci). δi = I(T
∗
i ≤ Ci) is the censoring indicator, which
is equal to 0 if the individual is censored and equal to 1 if the survival time was observed.
Now, the longitudinal regression is related to the survival via α in equation (133), where α =
{α1, ..., αK}, with αk denoting the relation of the kth longitudinal biomarker to survival.
If αk = 0, then this means that there is no relation between the survival time and the k
th
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longitudinal biomarker.
Let h(t) be an arbitrary function of the survival time. Two important cases are:
h(t) =
log(t), for an accelerated failure time modelt, for the other parametric models. (131)
For the ith individual the survival is modelled as
h(ti) = µi(ti) + σ × i, (132)
where σ is the log(scale) and µi(t) is given by
µi(t) =
∑
αkWik(t) +M
T
i γ, (133)
where γ is the regression coefficient that links the time-independent covariates, MTi , related
only to survival.
Denote by xTi (ttijk) and z
T
i (tijk) the rows of the design matrices X
T (tijk) and Z
T (tijk) from
equation (128). These vectors for the kth biomarker are observed at particular time points
tijk. Let tik, be the set of all time-points for the i
th individual and for the kth biomarker, i.e.
tik = {ti1k, ti2k, timik} with j = 1, · · · ,mi. Let us extend this notation to an arbitrary time
point t, to include the p× k matrix xTik(t), the q× k matrix zTik(t) and the kth longitudinal
biomarker Yik(tik).
Then, the joint model survival hi(t) for the i
th individual at an arbitrary (single) time-point
t is given by
hi(t) = αk[x
T
ik(t)β + z
T
ik(t)bik + u
T
ikλ] +M
T
i γ + σ × i. (134)
i is a vector of n×1, σ and α are numeric. Again, it is assumed that censoring and drop-out
mechanisms are non-informative. Specificaly, these two mechanisms are considered to be
independent of the random effects, the survival time and the longitudinal measurements,
(134).
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The joint likelihood contribution is given by
L(Yi, Ti, Ai, δi; θ) =
∫
L(Yi|bi; (θy, σ2e))L(Ti, Ai, δi|bi; (θt, σ2))φq(bi;D)dbi, (135)
where L(Yi|bi; (θy, σ2e)) =
∏K
k=1
{∏mi
j=1 φ (Yijk(tijk);Wijk(tijk), σ
2
e)
}
, (114).
The likelihood includes integral which is difficult to solve analytically, and thus an integral
approximation is needed. Gauss-Hermite or Laplace approximation can be applied and a
maximum likelihood can be used to estimate the parameters.
The next step is the development of a program implementing this methodology.
5.2 Competing Risks
In this section, let us assume that there are G− 1 distinct failure types.
5.2.1 Longitudinal Sub-model
Let ti = {tij, j = 1, 2, ...,mi}, be the set of mi time-points, at which the ith individual is
observed, these could differ for each individual, and Yi(ti) = {Yi(tij), j = 1, ...,mi} be a
vector of the observed values of a longitudinal biomarker.
Consider the following mixed linear model for the subject-specific observed values of the
longitudinal biomarker:
Yi(ti) = X
T
1i(ti)β1 + Z
T
1i(ti)b1i + U
T
1iλ1 + ei(ti), (136)
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where β1, λ1 and b1i are the vectors of p time-dependent fixed effects, r time-independent
fixed effects, and q random effects for the ith individual with the corresponding design
matrices XT1i(ti), U
T
1i, and Z
T
1i(ti), respectively. The matrix U
T
1i has m1i identical rows
uT1i. An m1i-vector of the independent and normally distributed measurement errors
e1i(tij) ∼ N (0, σ21e), so that the correlation between repeated measurements in the longitu-
dinal process is (e1i(tij), e1i(tij′)) = 0 for j 6= j′. The random effects b1i have multivariate
normal distribution, so that
b1i ∼MVN(0, D1), (137)
with a q1 × q1 variance-covariance matrix D1. The errors ei and the random effects bi are
mutually independent.
Denote by W1i(ti) = {W1i(tij), j = 1, ...,mi} the conditional expectation of the longitu-
dinal biomarker Yi(ti) given b1i. Then
E[Yi(ti)|b1i] = W1i(ti) = XT1i(ti)β1 + ZT1i(ti)b1i + UT1iλ1, (138)
and the longitudinal biomarker is given by
Yi(ti) = W1i(ti) + e1i(ti). (139)
Therefore conditionally on bi, the biomarker is normally distributed
Yi(tij)|b1i ∼ N (W1i(tij), σ21e) (140)
5.2.2 Marginal Failure Probability
The marginal probability of the ith subject failing from kth risk is given by:
pig(X2i,Wki; θ) =
exp
{
XT2i(ti)β2 + Z
T
2i(ti)b2i + U
T
2iλ2
}
)
1 +
∑G−1
g=1 exp {XT2i(ti)β2 + ZT2i(ti)b2i + UT2iλ2}
, (141)
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for g = 1, ..., G− 1, ((38),(39),(74),(65)).
β2, λ2 and b2i are the vectors of p2 time-dependent fixed effects, r2 time-independent fixed
effects, and q2 random effects for the i
th individual with the corresponding design matrices
XT2i(ti), U
T
2i, and Z
T
2i(ti), respectively. The matrix U
T
2i has m2i identical rows u
T
2i. The
random effects b2i have multivariate normal distribution, so that
b2i ∼MVN(0, D2), (142)
with a q2 × q2 variance-covariance matrix D2. All covariates here are denoted by XT2i(ti),
UT2i, and Z
T
2i(ti) because they may or may not differ than their corresponding X
T
1i(ti), U
T
1i,
and ZT1i(ti).
5.2.3 Cause-Specific Survival Sub-Model
For a specific survival component, let Ai, T
∗
i and Ci denote the left-truncation time, true
survival time and censoring time respectively, for the ith individual, i = 1, ..., n. The
observed survival time is given by Ti = min(T
∗
i , Ci). Denote by δi = I(T
∗
i ≤ Ci) the
censoring indicator (1-dead, 0-alive). Let MTi be the vector of the s time-independent
survival covariates, related only to survival.
Let h(t) be an arbitrary function of the survival time. Two important cases are:
h(t) =
log(t), for an accelerated failure time modelt, for the other parametric models. (143)
For the ith individual the survival is modelled as
h(ti) = µi(ti) + σ × i, (144)
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where σ is the scale parameter and i ∼ G(t) is an error term. The mean survival µi(t) is
given by
µi(t) = α1W1i(t) +M
T
i γ, (145)
where α is the association between the longitudinal and the survival sub-models, γ is the
s-vector of the regression coefficients, and MTi is the design matrix of s time-independent
survival covariates. When α = 0, there is no relation between the longitudinal and the
survival processes.
Denote by xT1i(ttij) and z
T
1i(tij) the rows of the design matrices X
T
1 (ti) and Z
T
1 (ti) from
the equation (136). These vector functions are observed at particular time points tij, j =
1, · · · ,mi but we extend this notation to an arbitrary time point t, to include the p-vector
xT1i(t), the q-vector z
T
1i(t) and the longitudinal biomarker Yi(t).
Then, the joint model survival hi(t) for the i
th individual at an arbitrary (single) time-point
t is given by
hi(t) = α[x
T
1i(t)β1 + z
T
1i(t)b1i + u
T
1iλ1] +M
T
i γ + σ × i. (146)
5.2.4 Joint Likelihood for Competing Risks
The joint likelihood for competing risks is given by:
L(Yi, Ti, Ai, δi; θ) =
∫
L(Yi|bi; (θy, σ2e))L(Ti, Ai, δi|bi; (θt, σ2))φq(bi;D)dbi, (147)
where
L(Ti, Ai, δi|bi; (θt, σ2)) =
g∏
k=1
{
f(t)pik(X2i,Wki; a))
δi(S(tpik(X2i,Wki; a))
1−δi} , (148)
((38),(39),(65),(74)), where f(t) and S(t) are the appropriate probability density and sur-
vival functions for the survival distribution under right-censoring or left-truncation and
100
right-censoring.
This likelihood also includes integral which is difficult to solve analytically, and thus an
integral approximation is needed. Gauss-Hermite or Laplace approximation can be applied
and a maximum likelihood can be used to estimate the parameters.
A program to implement this methodology is yet to be written.
5.3 Summary
In this chapter the future extensions of the shared parameter model developed in this
thesis are presented. These are a shared parameter model with multiple biomarkers and
competing risks, under left-truncation and right-censoring. These two, multiple biomarkers
and competing risks, are more complicated versions of the simple joint model presented in
this thesis. First of all, specific likelihoods for the appropriate survival distribution need
to be constructed. These likelihoods include integrals which cannot be solved analytically,
thus Gauss-Hermite or Laplace approximations can be applied. An R-program will be
developed for these two methods, multiple biomarkers and competing risks, and will be
tested using simulations.
It needs to be noted that there is no known methods for assessing the fit of a parametric
shared parameter model (even though there is some work for a shared parameter model
using a Cox proportional hazards survival sub-model), and this is also an issue that needs
to be investigated. First thoughts on this matter are to use the plot of a cumulative hazard
function of the Cox-Snell residuals against the Cox-Snell for assessing the overall fit of the
model, plot the scaled score residuals to identify how influential an observation is and
101
plot the Cook’s distance to identify influential subjects in respect to the estimation of the
parameters. These were discussed on Chapter 2 for assessing a parametric survival model’s
fit, but may or may not be suitable for a parametric shared parameter model.
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A Proof of fundamental survival analysis relations
The cumulative distribution function is given by
F (t) = P (T ≤ t), (A.1)
and the survival function is
S(t) = P (T > t). (A.2)
From (A.1) and (A.2):
S(t) = 1− F (t). (A.3)
The probability density function is related to the probability distribution by
f(t) =
d
dt
(F (t)). (A.4)
Differentiating the survival function,
S
′
(t) =
d
dt
(S(t)) =
d
dt
(1− F (t)) = −f(t). (A.5)
The hazard function is given by:
h(t) = lim
∆t→0
P [t ≤ T < t+ ∆t|T ≥ t]
∆t
. (A.6)
P [t ≤ T < t+ ∆t|T ≥ t] is the probability that t is in the interval (t+∆t)i.e.
P[t ≤ T < t+ ∆t|T ≥ t] = f(t), while P [T ≥ t] is the survival function (A.2). Thus,
h(t) =
f(t)
S(t)
. (A.7)
i
The cumulative hazard function is the sum of all individual hazards over time. It can be
expressed as an area under the curve h(u). So,
H(t) =
∫ t
0
h(u)du
=
∫ t
0
A.7︷ ︸︸ ︷
f(u)
S(u)
du
=
∫ t
0
A.5︷ ︸︸ ︷
−S ′(u)
S(u)
du
=
∫ t
0
︷ ︸︸ ︷
d
du
(− log(S(u)))
d
du
(log(S(u)))=
S
′
(u)
S(u)
= − log(S(t))
(A.8)
ii
B Transformations from distributions to models
B.1 Transformation from Log-Logistic distribution to Log-Logistic
Model
The survival function for the Log-Logistic distribution is given by:
S(t;λ, p) = (1 + λtp)−1. (B.1)
Taking the log transformation of time (y = log t) and redefining the parameters p = σ−1
and λ = exp {−σ−1µ}:
S(y;λ, p) = (1 + λ exp {py})−1 (B.2)
and Y follows a linear model:
Y = log T = µ+ σW, (B.3)
where W is the random variable from the standard logistic distribution with probability
density function:
fW (w) = exp {w}σ−1(1 + exp {w})−2 (B.4)
and survival function:
SW (w) = (1 + exp {w})−1. (B.5)
Thus, the probability density function of Y for the ith individual is:
f(yi;µi, σ) = exp
{
σ−1(yi − µi)
}
σ−1(1 + exp
{
σ−1(yi − µi)
}
)−2 (B.6)
and the survival function for the ith individual is:
S(yi;µi, σ) = [1 + exp
{
σ−1(yi − µi)
}
]−1. (B.7)
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C Application of Joint Modelling with Log-Logistic
Sub-model
The longitudinal component is modelled with a linear mixed effects model and the survival
component is modelled using Log-Logistic distribution.
The log survival time for the ith individual, following Log-Logistic distribution is given by
log Ti(ti) = µi(ti) + σ × i, (C.1)
where i comes from Logistic distribution, σ is the scale and µi(ti) is given by
µi(t) = αWi(t) +M
T
i γ, (C.2)
where γ is the regression coefficient that links the time-independent covariates, MTi , related
only to survival and Wi(t) is the longitudinal component.
The probability density and survival function of Log-Logistic model are given by (B.6)
and (B.7) respectively. For the longitudinal parts, the probability density functions of
Yi(tij) conditional on random effects bi and of random effects are given by (111) and (112)
respectively.
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C.1 Likelihood for Application of Joint Modelling with Log-Logistic
Sub-Model
C.1.1 Right-Censoring Likelihood for Application of Joint Modelling with
Log-Logistic Sub-Model
The Log-Logistic joint likelihood contribution for right-censoring only is
L(Yi, Ti, δi; θ) =
∏n
i=1 [
∫∞
−∞
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1b′iD−1bi)
×(exp {σ−1(log Ti(ti)− µi(ti))}σ−1(1 + exp {σ−1(log Ti(ti)− µi(ti))})−2)δi
×([1 + exp {σ−1(log Ti(ti)− µi(ti))}]−1)1−δi dbi ].
(C.3)
When Gauss-Hermite approximation is applied the likelihood becomes
L˜(Yi, Ti, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 [(2piσ2e)− 12
× exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1/2B−1EiD−121/2B−1Ei)
×(exp {σ−1(log Ti(ti)− µˆi(ti))}σ−1(1 + exp {σ−1(log Ti(ti)− µˆi(ti))})−2)δi
×([1 + exp {σ−1(log Ti(ti)− µˆi(ti))}]−1)1−δi ,
(C.4)
where Ŵi(tij) = X
T
i (tij)β +Z
T
i (tij)(2
1
2B−1Eili) +U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ. When
Laplace approximation is applied the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1bˆ′iD−1bˆi)
×(exp {σ−1(log Ti(ti)− µˆi(ti))}σ−1(1 + exp {σ−1(log Ti(ti)− µˆi(ti))})−2)δi
×([1 + exp {σ−1(log Ti(ti)− µˆi(ti))}]−1)1−δi ,
(C.5)
where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)bˆ+ U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ.
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C.1.2 Left-Truncation and Right-Censoring Likelihood for Application of Joint
Modelling with Log-Logistic Sub-Model
For the case of left-truncation and right-censoring, the likelihood becomes more compli-
cated.
L(Yi, Ti, Ai, δi; θ) =
∏n
i=1 [
∫∞
−∞
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1b′iD−1bi)
×([Ai(log(Ti(ti)) + Ai)]σ−1 [1 + exp[ logAi−µi(ti)σ ]]2
×[1 + exp[ log (Ti(ti)+Ai)−µi(ti)
σ
]]−2)δi
×[([1 + exp[ logAi−µi(ti)
σ
]][1 + exp[ log(Ti(ti)−Ai)−µi(ti)
σ
]]−1]1−δi dbi ].
(C.6)
When Gauss-Hermite approximation is applied the likelihood becomes
L˜(Yi, Ti, Ai, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 [(2piσ2e)− 12
× exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1/2B−1EiD−121/2B−1Ei)
×([Ai(log(Ti(ti)) + Ai)]σ−1 [1 + exp[ logAi−µˆi(ti)σ ]]2
×[1 + exp[ log (Ti(ti)+Ai)−µˆi(ti)
σ
]]−2)δi
×[([1 + exp[ logAi−µˆi(ti)
σ
]][1 + exp[ log(Ti(ti)−Ai)−µˆi(ti)
σ
]]−1]1−δi ,
(C.7)
where Ŵi(tij) = X
T
i (tij)β +Z
T
i (tij)(2
1
2B−1Eili) +U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ. When
Laplace approximation is applied the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1bˆ′iD−1bˆi)
×([Ai(log(Ti(ti)) + Ai)]σ−1 [1 + exp[ logAi−µˆi(ti)σ ]]2
×[1 + exp[ log (Ti(ti)+Ai)−µˆi(ti)
σ
]]−2)δi
×[([1 + exp[ logAi−µˆi(ti)
σ
]][1 + exp[ log(Ti(ti)−Ai)−µˆi(ti)
σ
]]−1]1−δi ,
(C.8)
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where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)bˆ+ U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ.
D Application of Joint Modelling with Log-Normal
Sub-Model
The longitudinal component is modelled with a linear mixed effects model and the survival
component is modelled using Log-Normal distribution.
The log survival time for the ith individual, following Log-Normal distribution is given by
log Ti(ti) = µi(ti) + σ × i, (D.1)
where i comes from Normal distribution, σ is the scale and µi(ti) is given by
µi(t) = αWi(t) +M
T
i γ, (D.2)
where γ is the regression coefficient that links the time-independent covariates, MTi , related
only to survival and Wi(t) is the longitudinal component.
The probability density and survival function of Log-Normal model are given in Table
(1). For the longitudinal parts, the probability density functions of Yi(tij) conditional on
random effects bi and of random effects are given by (111) and (112) respectively.
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D.1 Likelihood for Application of Joint Modelling with Log-
Normal Sub-Model
D.1.1 Right-Censoring Likelihood for Application of Joint Modelling with
Log-Normal Sub-Model
The Log-Normal joint likelihood contribution for right-censoring only is
L(Yi, Ti, δi; θ) =
∏n
i=1 [
∫∞
−∞
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1b′iD−1bi)
×[exp[−(Ti(ti)σ(2pi)1/2)−1[log Ti(ti)−µi(ti)]2
2σ2
]]δi
×[1− Φ( log(Ti(ti))−µi(ti)
σ
)]1−δi dbi ].
(D.3)
When Gauss-Hermite approximation is applied the likelihood becomes
L˜(Yi, Ti, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 [(2piσ2e)− 12
× exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1/2B−1EiD−121/2B−1Ei)
×[exp[−(Ti(ti)σ(2pi)1/2)−1[log Ti(ti)−µˆi(ti)]2
2σ2
]]δi
×[1− Φ( log(Ti(ti))−µˆi(ti)
σ
)]1−δi ,
(D.4)
where Ŵi(tij) = X
T
i (tij)β +Z
T
i (tij)(2
1
2B−1Eili) +U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ. When
Laplace approximation is applied the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1bˆ′iD−1bˆi)
×[exp[−(Ti(ti)σ(2pi)1/2)−1[log Ti(ti)−µˆi(ti)]2
2σ2
]]δi
×[1− Φ( log(Ti(ti))−µˆi(ti)
σ
)]1−δi ,
(D.5)
where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)bˆ+ U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ.
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D.1.2 Left-Truncation and Right-Censoring Likelihood for Application of Joint
Modelling with Log-Normal Sub-Model
For left-truncation and right-censoring case, the likelihood becomes more complicated.
L(Yi, Ti, Ai, δi; θ) =
∏n
i=1 [
∫∞
−∞
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)−Wi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1b′iD−1bi)
×[exp[(logAi − µi(ti))2 − (log (Ai + Ti(ti))− µi(ti))2]]δi
×[[1− Φ( log (Ti(ti)+Ai)−µi(ti)
σ
)][1− Φ( logAi−µi(ti)
σ
)]−1]1−δi dbi ].
(D.6)
When Gauss-Hermite approximation is applied the likelihood becomes
L˜(Yi, Ti, Ai, δi; θ) = 2
qn
2 |B|−n∏ni=1∑pli=1 ωli exp {E ′iEi}∏mij=1 [(2piσ2e)− 12
× exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1/2B−1EiD−121/2B−1Ei)
×[exp[(logAi − µˆi(ti))2 − (log (Ai + Ti(ti))− µˆi(ti))2]]δi
×[[1− Φ( log (Ti(ti)+Ai)−µˆi(ti)
σ
)][1− Φ( logAi−µˆi(ti)
σ
)]−1]1−δi ,
(D.7)
where Ŵi(tij) = X
T
i (tij)β +Z
T
i (tij)(2
1
2B−1Eili) +U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ. When
Laplace approximation is applied the likelihood becomes
L˜(Yi, Ti, δi; θ) = (2pi)
nq
2 Ωˆ−
n
2
∏n
i=1
∏mi
j=1 [(2piσ
2
e)
− 1
2 exp[−(Yi(tij)− Wˆi(tij))2(2σ2e)−1]]
×(2pi|D|)− 12 exp(−2−1bˆ′iD−1bˆi)
×[exp[(logAi − µˆi(ti))2 − (log (Ai + Ti(ti))− µˆi(ti))2]]δi
×[[1− Φ( log (Ti(ti)+Ai)−µˆi(ti)
σ
)][1− Φ( logAi−µˆi(ti)
σ
)]−1]1−δi ,
(D.8)
where Ŵi(tij) = X
T
i (tij)β + Z
T
i (tij)bˆ+ U
T
i λ and µˆi(ti) = αWˆi(t) +M
T
i γ.
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E Joint Modelling with Extreme Value for Survival
Sub-model
If the Extreme Value distribution, is preferred to be used for the survival sub-model,
it should be noted that when covariates are present, the log-likelihood, the probability
density function and the survival function (along with other quantities) of the extreme
value distribution have the same formulas as those for Weibull’s distribution. The only
difference is that there is no log tranformation of time ((63),(90), (97)).
F Joint Modelling with Gompertz Survival Sub-model
If Gompertz distribution is needed to fit the data, it can be achieved by using the Extreme
Value model. Under the transformations a = − log {σ}−µσ−1 and b = σ−1, the Gompertz
hazard function, becomes the Extreme hazard function. Thus, by fitting the Extreme
Value model, and using the above transformation, the Gompertz model is obtained ((3),
(97),(106)).
G Joint Modelling with Logistic Survival Sub-model
If the Logistic distribution, is preferred to be used for the survival sub-model, it should be
noted that when covariates are present, the log-likelihood, the probability density function
and the survival function (along with other quantities) of the Logistic model have the same
x
formulas as those for Log-Logistic’s distribution. The only difference is that there is no log
tranformation of time ((63),(90),(97)).
H Joint Modelling with Beard Survival Submodel
If Beard model is needed to fit the data, it can be achieved by using the Logistic model.
Under the transformations a = − log {σ}−µσ−1, b = σ−1 and ρ = log σ, the Beard hazard
function becomes the Logistic hazard function. Thus, by fitting the Logistic model, and
using the above transformation, the Beard model is obtained, ((3),(97),(106)).
I Joint Modelling with Perks Survival Submodel
If Perks model is needed to fit the data, it can be achieved by using the Beard (and
thus the Logistic) model. Under the transformation ρ = 0, the Beard hazard function,
becomes the Perks hazard function. Thus, by fitting the Beard model, and using the above
transformation, the Perks model is obtained, ((3),(97),(106)).
xi
J R documentation
J.1 Fitting Parametric Joint Models
Description
This function fits parametric joint models to right-censored data, and left-truncated and
right-censored data for Weibull, Log-Logistic, Log-Normal, Extreme and Logistic survival
distributions. Gompertz, Beard and Perks distributions can be obtained using the models
mentioned before as shown in the Appendix F, H and I respectively.
It obtains the maximum likelihood estimates, by maximizing the log-likelihood, using
Newton-Raphson algorithm i.e. xn+1 = xn− f
′
(x)
f(x)
. The algorithm uses starting parameters
obtained from survreg(), aftreg() and lme() functions.
Usage
fit.joint.model(dist="weibull",random=2,censored="right",
truncation="no",patient.in.longitudinal.form,
start.time.longitudinal,end.time.longitudinal,X1,Z1,U1,
censoring.longitudinal,M.longitudinal,
patient.in.survival.form,X2,Z2,U2,M,age=NULL,follow.up.time.for.survival,censoring.survival,
Y,nnodes,bootstrap=F,B)
xii
Arguments
patient.in.longitudinal.form: vector containing the patient id in a longitudinal form
X1: vector or matrix that includes all time-depedenent variables in a longitudinal form
Z1: vector or matrix with the random effects in a longitudinal form. It can only take up
to 2 random effects
U1: vector or matrix with time-independent variables in a longitudinal form
patient.in.survival.form: vector showing the patient id in a simple survival form
X2: vector or matrix that includes all time-dependent variable in a simple survival form
Z2: vector or matrix with the random effects in a survival form
U2: vector or matrix with time-independent variables in a survival form
M: vector or matrix with the survival covariates in a simple survival form
follow.up.time.for.survival: vector with the follow-up time for each patient in a simple
survival form
start.time.longitudinal: vector with the starting time for each patient in a longitudinal
xiii
form for each new observation
end.time.longitudinal: vector with the ending time for each patient in a longitudinal
form before the next observation
censoring.longitudinal: vector showing the status of the patient in a longitudinal form
(1-died,0-alive)
M.longitudinal: vector or matrix with the survival covariates in a longitudinal form
censoring.survival: vector showing the status of the patient in a survival form (1-died,0-
alive)
Y: vector showing the value of the longitudinal biomarker in a longitudinal form
random: 2 indicating 2 type of random effects, 1 indicating for 1 type of random effects
nnodes: the number of nodes to be used in Gauss-Hermite approximation
bootstrap: If TRUE, it performs a boostrap analysis with B number of replications
dist=”weibull”: One of the distributions Weibull, Log-Logistic, Log-Normal, Extreme,
Logistic. Additionally, Gompertz, Perks, Beard distributions can be obtained by using the
transformations mentioned in the Appendix.
censored=”right”: right-censoring only
xiv
truncation=”no”: ”no” or ”yes” (left-truncation only)
age=NULL: If truncation=”yes”, a vector with the starting ages of all individuals
Example
#taking a data that will be used from a library in R
>library(JM)
>Long=pbc2
>Surv=pbc2.id
>patient.in.longitudinal.form=Long$id
#patient id in longitudinal form
>patient.in.survival.form=Surv$id
#patient id in survival form
>X1=Long$year
#time in longitudinal form
>X2=Surv$year
#time in survival form
>Z1=Long$id
#random intercept in longitudinal form
>Z2=Surv$id
xv
#random intercept in survival form
>U1=rep(1,length(X1))
#longitudinal intercept in longitudinal form
>U2=rep(1,length(X2))
#longitudinal intercept in survival form
>M=rep(1,length(X2))
#survival intercept in survival form
>M.longitudinal=rep(1,length(X1))
#survival intercept in survival form
>follow.up.time.for.survival=Surv$years
#follow up time in survival form
>start.time.longitudinal=Long$year
#time for each longitudinal measurement
>end.time.longitudinal=Long$years
#time before the next longitudinal measurements
>censoring.longitudinal=Long$status2
#censoring in longitudinal form
>censoring.survival=Surv$status2
#censoring in survival form
xvi
>Y=Long$serBilir
#longitudinal biomarker in longitudinal form
>nnodes=2
#nodes for Gauss-Hermite
>B=100
#bootstrap samples
>age=pbc2.id$age
#age used for truncation time in left-truncated model
#fitting a left-truncated and right censored Weibull model
> fit.joint.model(dist="weibull",random=2,censored="right",
truncation="left",patient.in.longitudinal.form,
start.time.longitudinal,end.time.longitudinal,X1,Z1,U1,
censoring.longitudinal,M.longitudinal,
patient.in.survival.form,X2,Z2,U2,M,age=age,follow.up.time.for.survival,censoring.survival,
Y,nnodes,bootstrap=F,B)
J.2 Simulations
Description
This function simulates Weibull shared parameter model with patient observations 1 to 4
or 1 to 24. The a Weibull shared parameter model is fitted using analytical and bootstrap
xvii
methods.
It obtains the maximum likelihood estimates, by maximizing the log-likelihood, using
Newton-Raphson algorithm i.e. xn+1 = xn− f
′
(x)
f(x)
. The algorithm uses starting parameters
obtained from survreg(), aftreg() and lme() commands applied to the data.
Usage
autosimulation.generate(numberOfPatients,averageObservationCount,D,
alpha,beta,lambda,gamma,log.sigma,sigma.e,nnodes,B,
Simulations,Total.Simulations)
Arguments
numberOfPatients: the number of patients the user wants to simulate for the data
averageObservationCount: the number of observations the user wants to simulate. It
takes 3 and 23 which simulates 1to4 and 1to24 observations for each patient.
nnodes: the number of nodes the user wants to use for the Gauss-Hermite approximation
B: the number of bootstrap analyses to perform
Simulations: the number of successful simulations that is required for the program to
xviii
stop
Total.Simulations: the number of the total simulations that need to be performed until
the program will stop
The rest of the arguments D,alpha,beta,lambda,gamma,log.sigma, sigma.e would be D, α,
β, λ, γ and log σ respectively, that form the shared parameter model T ∗i (tij) = exp[α(tijβ+
bi + λ) + γ1 + γ2gi + σ × i], where the univariate random effects bi are generated from
N (0, D) and the errors ei(tij) are independently generated from N (0, σ2e) and γ = c(γ1, γ2).
Example
#Defining the actual values of the parameters
>D.1=0.1
#variance-covariance for the random effects
#constant
>alpha.1=1.0
#association between the longitudinal
#and survival procedures
>beta.1=1.0
#time-dependent longitudinal covariate
>lambda.1=1.0
#time-independent longitudinal covariate
xix
>gamma.1=1.0
#survival covariate
>log.sigma.1=0.1
#log(scale) for the survival model
>sigma.e.1=0.1
#longitudinal variance for the longitudinal model
>nnodes.1=2
#Gauss-Hermite nodes to be used
>numberOfPatients.1=100
#number of patients to be simulated
>averageObservationCount.1=3
#average observations for the patients
#when it is 3, they have observation from 1 to 4
>B.1=100
#bootstrap samples
>Simulations.1=500
#total replications until the simulation are finished
>Total.Simulations.1=500
#total replications for the simulations
xx
#begin the simulations program
>SKEVI1=autosimulation.generate(numberOfPatients.1,
averageObservationCount.1,D.1,alpha.1,beta.1,
lambda.1,gamma.1,log..sigma.1,sigma.e.1,nnodes.1,
B.1,Simulations.1,Total.Simulations.1)
xxi
